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Abstract
Diversity within a population of organisms is typically ascribed to genetic differences.
However, even members of a genetically identical group of cells or organisms in identical
environments can exhibit variability in state and phenotype. One striking example of such
heterogeneity is revealed when a genetically identical population of human cells is exposed to
saturating doses of a death-inducing drug called TRAIL - many cells in the population will
undergo apoptosis, a form of controlled cell death, but a fraction of cells always survives the
treatment.
The goal of this thesis was to understand the origins of variability in both the timing and
the probability of death in TRAIL-induced apoptosis. To this end, both experimental and
computational methods were implemented. Experiments examining the response of sister cells
to TRAIL provided strong evidence that variability in initial conditions played a key role, and
ruled out genetic, stochastic, and cell cycle effects as possible causes of heterogeneity in
response. A detailed analysis of the relative contributions of three segments of the TRAIL
pathway revealed that the majority of the variability in time-to-death arose upstream of
mitochondrial outer membrane permeabilization (MOMP), with little contribution from
downstream reactions. More specifically, the rate of cleavage of initiator caspase substrates was
highly predictive of a cell's death time. However, to determine whether (as opposed to when) a
cell will die, variation in the MOMP threshold became critical. This dependency was indicated
by observation of the height of the MOMP threshold in surviving and dying cells and by
modulation of this threshold via overexpression of anti-apoptotic regulators of MOMP.
Simulations of cell-to-cell variability in TRAIL-induced apoptosis confirmed that the
endogenous variability in apoptotic regulators was sufficient to produce the observed variability
in death time. However, knowledge of the concentration of individual proteins did not allow
prediction of death time because variation in other proteins masked the underlying trends. The
ability to simulate heterogeneity in cellular response also led to the development of novel,
biologically intuitive methods of sensitivity analysis, which revealed that sensitivities shift
depending on whether knowledge of covariance in initial conditions is included.
The ability to predict sensitivity and resistance of tumors to TRAIL would be clinically
valuable, as TRAIL is currently in clinical trials as an anti-cancer therapy. The results described
here represent progress toward understanding the "fractional killing" of tumor cells following
exposure to chemotherapy, and for understanding variability in mammalian signaling pathways
in general.
Supervisor: Peter Sorger, Ph.D.
Title: Professor of Systems Biology, Harvard Medical School
Professor of Biological Engineering, Massachusetts Institute of Technology
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Chapter 1
1 Introduction
The description of apoptosis 37 years ago (Kerr, Wyllie et al. 1972) and the subsequent
identification of the core set of regulatory genes in C. elegans (Ellis and Horvitz 1986) inspired
the modem era of apoptosis research, but the critical role of cell death in development and
homeostasis of multicellular organisms had been appreciated for over 100 years (Clarke and
Clarke 1995). In a healthy adult human, billions of cells die each hour in the intestine and bone
marrow; this loss of cells must be balanced by an equal number of cell divisions to maintain
constant body size (Vaux and Korsmeyer 1999; Alberts, Johnson et al. 2002). An imbalance in
the amount of apoptosis relative to the level of proliferation can result in diseases such as
neurodegenerative and auto-immune disorders in the case of too much apoptosis or cancer in the
case of too little apoptosis. In fact, the discovery that the anti-apoptotic protein Bcl-2 is often
over-expressed in cancer was the first indication that cancer is a result not only of over-active
proliferation but also of suppressed apoptosis (Vaux, Cory et al. 1988; Hockenbery, Nunez et al.
1990). The ultimate goal of cancer treatment is to induce apoptosis in cancer cells while leaving
normal cells unaffected (Letai 2008). However, cancer cells can be refractory to chemotherapy
for a variety of reasons including genetic mutations causing resistance to the drug or
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ineffectiveness of the drug if a cell is passing through a certain phase of the cell cycle (Skeel
2003). These two explanations are the most frequently quoted for why some cells live and some
cells die in response to chemotherapy. However, beyond these two explanations, there are a
number of other factors that can also contribute to partial chemotherapy resistance, such as
heterogeneity in the tumor microenvironment and local interaction with stromal cells. Largely
unaddressed is whether natural fluctuations in the levels or activity states of proteins and other
biomolecules produce sufficient variation from cell to cell to have an impact on a cell's fate after
an apoptotic trigger. It is this question that my thesis addresses.
1.1 Specific Aims
The overall goal of this thesis was to examine the causes of non-genetic variability in
apoptosis at the single cell level. The first aim was experimental in nature, and focused primarily
on the origins of heterogeneity in the timing of TRAIL-induced apoptosis. These experiments
involved tracking cell pedigrees with time-lapse imaging to determine whether cells with similar
initial conditions would die at similar times. Live-cell microscopy of apoptotic events,
monitored with fluorescent reporters, was used to determine which biochemical reactions were
primarily involved in generating this variability in death time. Lastly, the levels of various
proteins involved in cell death were varied to asses their impact on the timing of apoptosis.
The second aim computationally addressed how variability in the levels of apoptotic
regulators propagated through the network to produce heterogeneity in the apoptotic response. A
population of cells was modeled with a population of models, with variability in each 'cell'
produced by sampling from measured distributions of protein levels. Using this framework, the
sensitivities of apoptotic regulators, the impact of correlations in initial conditions, and the
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degree to which knowledge of individual protein levels allows prediction of cellular death time
were assessed.
The third aim was again experimental in nature and examined the differences between
cells that survive TRAIL treatment and cells that succumb. Cells that survived a first TRAIL
stimulation were re-challenged with TRAIL and assessed for their ability to resist this second
treatment as well as the duration of any refractory period. Next, the biochemical reactions
governing the approach to the 'point of no return' (mitochondrial outer membrane
permeabilization - MOMP) were monitored in single cells to identify the features of cells that do
and do not cross this threshold. Finally, the reactions at the MOMP threshold that convert a
gradual buildup of pro-apoptotic signals to a switch-like commitment to death were examined.
1.2 Cell-to-cell variability
Diversity within a population of organisms is typically ascribed to genetic differences.
However, even members of a genetically identical group of cells or organisms in identical
environments can exhibit variability in state and phenotype. Only in the last decade have the
origins of non-genetic variability begun to be addressed in mechanistic terms. A thorough
review of this topic was recently published (Raj and van Oudenaarden 2008); here I highlight the
literature relevant to this thesis.
1.2.1 Origins of noise in gene expression in prokaryotes and lower eukaryotes
"Non-genetic individuality" in bacterial chemotaxis was first reported over 30 years ago
(Spudich and Koshland 1976), but it was not until the late 1990s that theoretical work on
stochastic gene expression prompted interest in the sources of this noise (McAdams and Arkin
1997; Arkin, Ross et al. 1998). This theoretical work modeled stochastic chemical kinetics to
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show that protein numbers could fluctuate significantly and that these fluctuations could
contribute to the apparently stochastic decision to activate the lytic or lysogenic pathway of
lambda phage (McAdams and Arkin 1997; Arkin, Ross et al. 1998).
The first experiment to analyze the sources of noise in gene expression involved tagging
two copies of the same promoter with a fluorescent protein in E. coli - one with cyan fluorescent
protein (CFP) and one with yellow fluorescent protein (YFP) (Elowitz, Levine et al. 2002). This
system allowed the authors to distinguish between "extrinsic noise" (fluctuations that affect both
copies of the gene equally in the same cell, but may vary from cell to cell) and "intrinsic noise"
(fluctuations caused by the inherent stochasticity in transcription and translation). If cell-to-cell
variability in protein levels were due only to intrinsic flucutations, the CFP and YFP levels
would not be correlated in a single cell; if noise were only due to extrinsic fluctuations, CFP and
YFP levels would be tightly correlated. The authors found that both sources of noise contributed
to produce cell-to-cell variability in gene expression (Fig. 1.1).
The van Oudenaarden group predicted (Thattai and van Oudenaarden 2001) and showed
experimentally (Ozbudak, Thattai et al. 2002) that the variability in protein expression level in a
population would be anti-correlated with the rate of transcription, but would be unaffected by the
rate of translation because proteins are produced rapidly in "bursts" from a single transcript.
Subsequent studies in eukaryotes (initially yeast and later higher eukaryotes) found that the
sources of noise were different from those in prokaryotes in several ways (Blake, M et al. 2003;
Raser and O'Shea 2004; Becskei, Kaufmann et al. 2005; Blake, Balazsi et al. 2006). The
observed differences were compatible with models encoding transcriptional bursts in which a
gene randomly switches between transcriptional activity and inactivity. A likely explanation is
- 16-
chromatin remodeling, for which there is suggestive but no direct evidence (Raj and van
Oudenaarden 2008).
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Figure 1.1. Intrinsic and extrinsic noise can be measured and distringuished with two genes (cfp, shown in green;
yfp shown in red) controlled by identical regulatory sequences. Cells with the same amount of each protein
appear yellow, whereas cells expressing more of one fluorescent protein than the other appear red or green. a, In
the absence of intrinsic noise, the two fluorescent proteins fluctuate in a correlated fashion over time in a single cell
(left). Thus, in a population, eachcell will have the same amount of both proteins, although that amount will differ
from cell to cell because of extrinsic noise (right). b, Expression of the two genes may become uncorrelated in
individual cells because of intrinsic noise (left), giving rise to a population in which some cells express more of one
fluorescent protein thatn the o ther(right). c, Expected cell-to-cell variations when fluctuations are intrinsic, extrin-
sic, or both. d, E. coil showing significant amounts of intrinsic noise. CFP and YFP fluorescence images were
combined in the green and red channels, respectively. a, b and d are reprinted from Science, 297(5584), Elowitz
MB, Levine AJ, Siggia ED, Swain PS. "Stochastic gene expression in a single cell", 1183-6, (2002), with permission
from Elsevier. c is reprinted from Cell, 135(2), Raj A, van Oudenaarden A. "Nature, nurture, or chance: stochastic
gene expression and its consequences", 216-26, (2008), with permission from AAAs.
Noise in gene expression in yeast is primarily extrinsic in origin, with contributions from
cell size, cell cycle state, variations in common upstream factors, and location of the gene being
transcribed (Raser and O'Shea 2004; Becskei, Kaufmann et al. 2005; Newman, Ghaemmaghami
et al. 2006; Volfson, Marciniak et al. 2006). In support of this, one study quantified the various
sources of noise on the yeast mating pheromone response pathway and found that most of the
variability was due to pre-existing differences between cells that propagate the signal (Colman-
Lerner, Gordon et al. 2005). In multicellular eukaryotes, despite the larger cell size and
17-
increased number of molecules, cell-to-cell variability can be considerable. Reports studying
Dictyostelium and Chinese hamster ovary cells have found that transcriptional bursts are
infrequent but long-lasting, producing high variation from cell to cell in mRNA number (Chubb,
Trcek et al. 2006; Raj and van Oudenaarden 2008).
Another important consideration is the role of network architecture on noise propagation,
minimization, and amplification. Noise in an upstream regulator was found to propagate to a
downstream gene, adding to the intrinsic noise inherent in the downstream gene's output
(Pedraza and van Oudenaarden 2005). Negative and positive feedback loops are common
network motifs found in biology. Negative feedback can reduce the effects of noise in a system,
bringing the signal back to the set point by correcting deviation from that set point (Becskei and
Serrano 2000; Austin, Allen et al. 2006; Dublanche, Michalodimitrakis et al. 2006). Positive
feedback can have the opposite effect, acting to amplify small fluctuations, potentially flipping a
switch from an "on" to an "off' state. Cooperativity can act to maintain a given state, buffering
it against small fluctuations which could flip its state, and providing a long-term protein-level
memory. This bistability has been observed in networks containing positive feedback loops,
such as spontaneous entry into competence (a transiently differentiated state where DNA can be
taken up from the environment) in Bacillus subtilis (Suel, Garcia-Ojalvo et al. 2006; Suel,
Kulkarni et al. 2007).
In the last decade, much has been learned about the causes of noise in gene expression.
There is now increasing interest in assessing whether cell-to-cell differences in protein levels
resulting from noisy gene expression have important physiological consequences for cells, or
whether cells have evolved to be robust to these fluctuations.
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1.2.2 Variability in the behavior of mammalian cells
Studies of variability in mammalian cells are less common, and variability at the gene and
protein levels is rarely linked to variability in phenotypic outcome, although it is known that cells
can vary widely in their responses to physiological stimuli. Since the start of this thesis work
(June 2005), several research papers have been published on the topic of variability in
mammalian cells.
A pioneering study measured fluctuations in the levels of 20 endogenous proteins over
time in living human cells (Sigal, Milo et al. 2006). The proteins were tagged with YFP at their
endogenous locus and tracked by live cell microscopy under normal growth conditions for
several generations. This method allowed dynamic observation of protein level heterogeneity
and examined whether cells that have higher than average protein levels eventually become
lower. This mixing occurred for all proteins, and the half-life for mixing time was found to
range between 0.8 cell generations for proteins with narrowly distributed expression and 2.5 cell
generations for proteins with broadly distributed expression (Fig. 1.2). This persistent memory
of protein levels could result in 'outlier' cells and may underlie variability in cell behavior. The
observed long-lasting memory suggests that several cell cycles might be needed for a population
of cells to reach a certain multidimensional state where all cells will be fully affected by a certain
drug or signal; this finding is relevant to the results in Chapter 4.
Other studies have examined variability in cell behavior after some perturbation. For
example, live cell microscopy has been used to study the oscillatory dynamics of the tumor
suppressor p53 after DNA damage (Lahav, Rosenfeld et al. 2004; Geva-Zatorsky, Rosenfeld et
al. 2006). These studies found that identical cells respond very differently to DNA damage -
some cells had zero pulses of p53, while others oscillated for three days (more than 10 peaks)
(Lahav, Rosenfeld et al. 2004; Geva-Zatorsky, Rosenfeld et al. 2006). Single-cell imaging of
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NFB localization after stimulation with tumor necrosis factor alpha (TNFa) also revealed
asynchronous oscillations (Nelson, Ihekwaba et al. 2004).
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Figure 1.2. a, Possible mixing
dynamics of a protein in a popula-
tion of cells. b, c, Dynamics of
cells expressing YFP-tagged
USP7 and HMGA2 across two
cell generations. Each line
represents the protein level of one
cell, normalized to the population
mean. d, e, Ranks of 60
randomly selected cells for USP7
and HMGA2 through two cell
generations, where 1 is the lowest
and 60 is the highest protein level
in the population at the given time
point. Lines are colour-coded for
rank at the start of the first cell
cycle, with red being high relative
to the mean and blue low. From
these data, the auto-correlations
of protein level ranks are calcu-
lated. Reprinted by permission
from Macmillan Publishers Ltd:
Nature, 444(7119), Sigal A, Milo
R, Cohen A, Geva-Zatorsky N,
Klein Y, Liron Y, Rosenfeld N,
Danon T, Perzov N, Alon U.
"Variability and memory of protein
levels in human cells", 643-6,
(2006).
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Flow cytometry was used in three recent studies to observe the effects of endogenous
variability in protein levels. In one study, variability in the activation of a clonal population of T
cells could be linked to endogenous variability in the levels of two proteins, CD8 and SHP-1
(Feinerman, Veiga et al. 2008). Another study found significant heterogeneity in the levels of
the stem cell marker, Sca-1 (Chang, Hemberg et al. 2008). Sorting for cells with low and high
Sca-1 levels revealed that the level of this protein governs the propensity to differentiate into the
erythroid or myeloid lineage (Chang, Hemberg et al. 2008). A second independent but related
report observed noteworthy heterogeneity in the expression levels of the stem cell master
regulator, Nanog (Chambers, Silva et al. 2007). This group observed a reduced capacity for self-
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renewal in embryonic stem cells sorted to have low Nanog levels and an increased propensity to
differentiate in cells sorted to have high Nanog levels (Chambers, Silva et al. 2007).
The first studies to note that apoptosis proceeds at different rates in different cells were
published in 2000 (Goldstein, Kluck et al. 2000; Tyas, Brophy et al. 2000). One report noted
that stronger apoptotic stimuli induce earlier death but found no correlation between the time of
onset of apoptosis and the duration of the apoptotic process (Goldstein, Kluck et al. 2000). Both
of these results were later confirmed by our group in a dynamic study of apoptosis in single cells
using live-cell reporters of apoptotic events (Albeck, Burke et al. 2008a; Albeck, Burke et al.
2008b). Another study characterized the response of 15 cell lines to three different classes of
antimitotic drugs and found significant inter- as well as intra-line variation, with cells within any
given cell line exhibiting multiple behaviors in response to treatment (Gascoigne and Taylor
2008). A recent paper identified two proteins whose levels rise in cells that survive treatment
with the cancer drug camptothecin and decrease in cells that died, thereby correlating variability
arising subsequent to treatment with cell fate (Cohen, Geva-Zatorsky et al. 2008). However, the
cause of this bifurcation in protein levels was not addressed, preventing a priori prediction of
which cells will live and which will die.
In summary, the origins of variability in protein levels have been well described in
prokaryotes and yeast, the time-scale of protein level fluctuations in unperturbed human cells has
been characterized, and variability has been observed in several signaling pathways including
DNA damage, T cell activation, differentiation, and apoptosis. However, no study has examined
whether pre-treatment protein-level variability has any cell fate consequences in the context of
apoptosis.
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1.2.3 Modeling cell-to-cell variability
As it becomes feasible to study single cells rather than the average behavior of a
population, new modeling frameworks will be required to describe this heterogeneity.
Continuous deterministic models are appropriate when the number of reactants is large, but will
become inaccurate when the number of reactants falls below -10, as molecular populations
change by discrete integer amounts. The dynamics of such a biological system can be modeled
using a stochastic Markov jump process where any change to the system occurs discretely after a
random period of time (Wilkinson 2009). This type of process is generally simulated with a
stochastic simulation algorithm (Gillespie 1977), which was notably applied to stochastic gene
expression (McAdams and Arkin 1997; Arkin, Ross et al. 1998).
In mammalian cells, however, the number of reactants in protein signal transduction
pathways is rarely low enough to require stochastic simulations and yet mammalian cells can still
vary in phenotype and response. As described in Section 1.2.1, cells are subject to sources of
variability other than noise in kinetic biochemical reactions (intrinsic noise). For example, cells
may behave differently from one another because they have different initial conditions (RNA or
protein levels, activity states, or localizations) at the start of the experiment. This type of
variability has previously been referred to as "extrinsic noise" (see Section 1.2.1), but in this
work will be referred to as variability in initial conditions. This type of pre-existing variability
can be modeled using deterministic equations with random sampling of a distribution of initial
conditions, thereby taking into account differences in the starting state of each cell. There is
currently no literature which uses a deterministic framework with random sampling of initial
conditions to model a population of cells, allowing one to examine how this input variability
propagates through a network to produce cell-to-cell variability in a biological response. Such
research is the topic of Chapter 3.
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1.3 Apoptosis
The apoptotic form of cell death is defined by the controlled activation of caspases; it is
often contrasted with necrotic death of cells due to injury causing rupture of the cells and a
strong inflammatory response. A hallmark feature of apoptosis is that the cell is internally
dismantled into membrane-bound fragments ("apoptotic bodies") in a controlled fashion that
recruits macrophages to engulf apoptotic cells without causing an inflammatory response from
the organism (Leist and Jaattela 2001). Apoptosis plays a key role in the development of
multicellular organisms as well as in the homeostasis of adult organisms. During development,
cells that are produced in excess are eliminated via apoptosis and thus this process is critical for
the proper sculpting of organs and tissues (Meier, Finch et al. 2000). An oft-cited example of the
role of apoptosis in animal development is the formation of free and independent digits by
apoptosis of the interlinking tissue (Zou and Niswander 1996; Zuzarte-Luis and Hurle 2002).
Another example is the control of the size and connectivity of the developing brain, where more
than half of the neurons that are initially created die by apoptosis (Hutchins and Barger 1998).
The key role of apoptosis in the biology of organisms implicates this process in a number
of diseases and pathologies. A decrease in the required amount of apoptosis can result in
diseases such as cancer, auto-immune diseases, and the spreading of viral infections. In contrast,
neurodegenerative disorders, AIDS, and ischemic diseases are caused or enhanced by excessive
apoptosis (Fadeel, Orrenius et al. 1999). The role of apoptosis in the development of cancer is
especially relevant for this thesis. Cells with severely damaged DNA that cannot be repaired or
cells with inappropriate mitogenic signaling are instructed to die by apoptosis. If they fail to do
so, cancer may develop and in fact, evasion of apoptosis is a hallmark of cancer (Hanahan and
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Weinberg 2000). The first oncogene found to cause cancer by preventing apoptosis rather than
promoting proliferation was Bcl-2, an anti-apoptotic protein found to be overexpressed by
chromosomal translocation in follicular lymphoma and other cancers (Vaux, Cory et al. 1988;
Hockenbery, Nunez et al. 1990).
There are two major signaling pathways that lead to apoptosis in mammalian cells - the
intrinsic pathway, and the extrinsic or receptor-mediated pathway studied in this thesis. Intrinsic
apoptosis is triggered by signals originating inside the cell, such as DNA damage, oxidative
stress, and starvation (Kaufmann and Earnshaw 2000; Wang 2001). Some of these signals
converge on the tumor suppressor p53, which can stimulate expression of a variety of apoptosis-
inducing genes causing a change in the balance of pro- and anti-apoptotic factors. This leads to
permeabilization of the mitochondria, followed by effector caspase activation and death of the
cell (Miyashita and Reed 1995; Vousden and Lu 2002). In receptor-mediated apoptosis, a
protein signaling network controls the transmission of a death signal from receptors on the cell
surface to effector caspases that cause cell death, as described below.
1.3.1 The TRAIL-mediated apoptosis pathway
The TRAIL-induced apoptosis pathway is triggered by the binding of TNF-related
apoptosis inducing ligand (TRAIL) to its receptors on the cell surface (Fig. 1.3, green arrow).
TRAIL is a member of the TNF (tumor necrosis factor) family of death ligands which include
TRAIL, FasL, and TNFa, each of which binds to a unique receptor(s). There are two receptors
for the TRAIL ligand, DR4 and DR5, which trimerize upon ligand binding. This event triggers
assembly of the death-inducing signaling complex (DISC), which recruits several adaptor
proteins, including Fadd (Fas-associated death domain) and FLIP (cellular FLICE-inhibitory
protein) (Kischkel, Hellbardt et al. 1995; Medema, Scaffidi et al. 1997). Fadd recruits initiator
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caspases 8 and 10 (hereafter referred to as C8), which are activated by conformational changes
resulting from induced dimerization (Boatright, Renatus et al. 2003; Donepudi, Mac Sweeney et
al. 2003). Autocatalytic processing of C8 then occurs and the resulting mature C8 dimer is
released into the cytosol (Chang, Xing et al. 2003). The activation of C8 is regulated by FLIP, a
protein that is structurally similar to C8 but lacks catalytic activity (Irmler, Thome et al. 1997).
At low levels, FLIP can act as an enhancer of C8 activation by acting as a dimerization partner
for C8; at high concentrations, FLIP can act as a "dominant-negative" by competing for C8
binding at the DISC (Chang, Xing et al. 2002; Boatright, Deis et al. 2004).
Figure 1.3. The TRAIL-induced apoptosis
ax Bc-2 pathway. Green arrow, TRAIL-receptor binding
C8 ax and activation of the DISC. Orange arrow,
initiator caspase cleavage of effector caspases.
C6ore Blue arrow, the mitochondrial outer membrane
XIA S permeabilization pathway. Gray arrow, poten-
C3 ftial positive feedback through caspase-6.
CyC Reporter proteins IC-RP, EC-RP, and IMS-RP
...................... 
are indicated. See text for details.
SApoptosome
Activated C8 can directly cleave and activate effector caspases 3 and 7 (hereafter C3; Fig
1.3, orange arrow), which are normally present in the cell as inactive pro-caspase homodimers
(Pop, Chen et al. 2001). The activating cleavage by C8 enables a conformational change
allowing it to form a heterotetramer that opens the active site (Bose, Pop et al. 2003). However,
active C3 is held in check by XIAP (X-linked inhibitor of apoptosis) until the mitochondrial
pathway is triggered. XIAP is a potent inhibitor of caspases-3, and -7 with inhibition constants
of 0.7 and 0.2 nM, respectively (Deveraux, Takahashi et al. 1997). XIAP also contains a RING
domain which mediates degradation of active effector caspases via its E3-ubiquitin ligase
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activity (Suzuki, Nakabayashi et al. 2001); XIAP can also regulate its own levels by auto-
ubiquitination (Yang, Fang et al. 2000).
The mitochondrial pathway can be thought of as a feedforward loop (Fig. 1.3, blue
arrow) controlled by pro- and anti-apoptotic Bcl-2-family proteins. In most cell types (often
referred to as "type II"), including those examined in this thesis, the feedforward amplification
provided by the mitochondrial pathway is required for death. This pathway is activated because
C8 also cleaves Bid to activated tBid, a member of the "activator" class of pro-apoptotic Bcl-2
proteins, so called because they in turn activate "effectors" Bax and homolog Bak by induced
conformational change (Wei, Lindsten et al. 2000; Wei, Zong et al. 2001; Kuwana, Mackey et al.
2002; Letai, Bassik et al. 2002). Active Bax translocates to the mitochondria, where it
multimerizes and acts to form pores in the mitochondrial outer membrane; Bak is naturally
present in the mitochondrial outer membrane (Kuwana, Mackey et al. 2002). The pro-apoptotic
activity of "activators" and "effectors" is antagonized, however, by the anti-apoptotic Bcl-2
family proteins (including Bcl-2, Bcl-xL, and Mcl-1) (Oltvai, Milliman et al. 1993; Cheng, Wei
et al. 2001). These proteins act as a buffer for activated tBid, Bax, and Bak. When these
proteins overwhelm the buffer, pores are formed and MOMP, or mitochondrial outer membrane
permeabilization, occurs. In effect, the levels of pro-apoptotic tBid, Bax, and Bak and the anti-
apoptotic Bcl-2 (and homologs) set an threshold for MOMP, which is considered to be the "point
of no return" in apoptosis (Keeble and Gilmore 2007). This threshold can also be indirectly
altered by proteins of the "sensitizer" class, which are structurally similar to the "activator" class,
but which cannot directly activate Bax and Bak (Letai, Bassik et al. 2002). Rather, "sensitizers"
(such as Bad, Noxa, and BMF) bind to free anti-apoptotic Bcl-2 family proteins, distracting them
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from interacting with Bax and Bak, and effectively lowering the threshold for MOMP (Letai,
Bassik et al. 2002).
Once MOMP occurs, a potent mixture of pro-apoptotic proteins, including cytochrome c
and Smac are released from the mitochondrial intermembrane space in an "all-or-none" fahsion.
Cytochrome c forms the apoptosome complex with Apaf-1 and caspase-9, which activates
additional C3 (Li, Nijhawan et al. 1997; Rodriguez and Lazebnik 1999; Kim, Du et al. 2005).
This activation is aided by Smac's inhibition of XIAP, freeing C3 from its XIAP-inhibited state
(Du, Fang et al. 2000; Verhagen, Ekert et al. 2000). A positive feedback loop mediated by
caspase-6 serves to amplify the death signal under certain conditions (Fig 1.3, gray arrow),
although this feedback does not seem to be important in the HeLa cells used in this thesis
(Albeck, Burke et al. 2008b).
C3 goes on to kill the cell by destroying its genome and proteome. The genome is
dismantled via C3 cleavage of ICAD (inhibitor of caspase-activated DNAses). ICAD is typically
bound to CAD, holding the DNAse activity of CAD in check. When ICAD is cleaved by
caspases, CAD is released and creates double-strand breaks in the DNA, fragmenting the
genome (Liu, Li et al. 1998; Inohara, Koseki et al. 1999). Another important category of C3
substrates are DNA repair enzymes such as PARP (poly-ADP-ribose polymerase). Cleavage of
PARP is often used as a marker for C3 activity (Kaufmann 1989; Tewari, Quan et al. 1995;
Fischer, Janicke et al. 2003). A third category of C3 substrates relevant to this thesis includes
structural proteins, such as cytokeratins and nuclear lamins, whose cleavage results in the
characteristic apoptotic morphology of cell deformation and shrinking (Fischer, Janicke et al.
2003).
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1.3.2 TRAIL's natural role in the organism
TRAIL is a ligand native to the human body that is highly expressed by natural killer
cells, and may be induced on other leukocytes (Griffith, Wiley et al. 1999; Smyth, Cretney et al.
2001; Takeda, Hayakawa et al. 2001). The presumed biological function of TRAIL is the
immune surveillance of tumors, as it has been shown to act as a tumor suppressor in mouse
experimental tumor models. For example, two studies showed that TRAIL is important for
suppressing sarcomas induced by the chemical carcinogen methylcholanthrene either by
administering a neutralizing anti-TRAIL antibody (Takeda, Smyth et al. 2002) or by performing
the study in TRAIL-deficient mice (Cretney, Takeda et al. 2002). A third study observed
spontaneous lymphoid malignancies over the life-span of TRAIL-deficient mice (Zerafa,
Westwood et al. 2005).
However, given the incidence of cancer, many tumors must be able to evade immune
surveillance. There are a variety of mechanisms by which cancer cells do this; specific to the
TRAIL pathway, several genetic lesions have been associated with human tumor onset and
progression. The TRAIL receptors DR4 and DR5 maps to human chromosome 8p21-22, a
region that is frequently lost in tumors (Johnstone, Frew et al. 2008). Mutations in DR5 have
been identified in a proportion of various human tumors, including breast, lung, head and neck,
and non-Hodgkin lymphoma (Lee, Shin et al. 1999; Fisher, Virmani et al. 2001; Lee, Shin et al.
2001; Shin, Kim et al. 2001), and there is some (weaker) evidence for mutations in DR4,
caspase-8, and Flip causing cancer predisposition (Johnstone, Frew et al. 2008).
1.3.3 TRAIL as a chemotherapy
A main goal of cancer treatment via radiation and chemotherapy is to induce the death of
cancer cells by apoptosis. Cancer cells often 'harbor the seeds of their own destruction': the very
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oncogenic mutations that allow them to aberrantly proliferate also have the potential to trigger
the apoptotic program (Lowe, Cepero et al. 2004). Thus, cancer cells can be particularly
sensitive to therapies that re-establish the pro-apoptotic signaling that these abnormal cells have
found a way to suppress. Cancer cells may be closer to crossing the threshold for initiation of
apoptosis than normal cells, so drugs like ABT-737 (which relieve Bcl-2, Bcl-w, and Bcl-xL's
inhibition of pro-apoptotic Bcl-2 family members) are likely to be effective strategies for cancer
cells that are "primed" for death (Letai 2008).
The enthusiasm over TRAIL as a cancer treatment is a result of early observations that it
preferentially kills cancer cells over normal cells, and is safe to administer systemically, unlike
death ligands FasL and TNFc (Walczak, Miller et al. 1999; Bouralexis, Findlay et al. 2005).
Many papers have been published citing various factors responsible for the respective resistance
and sensitivity of normal and cancer cells to TRAIL; other studies have compared sensitive and
resistant cancer cell lines, producing a similarly long list of critical factors (reviewed in ref.
Zhang and Fang 2005). Briefly, expression of three antagonistic TRAIL decoy receptors (DcR1,
DcR2, and osteoprotegerin) was initially thought to be responsible for resistance to TRAIL by
competing with DR4 or DR5 for TRAIL binding (Degli-Esposti, Dougall et al. 1997; Degli-
Esposti, Smolak et al. 1997; Pan, Ni et al. 1997; Sheridan, Marsters et al. 1997; Emery,
McDonnell et al. 1998). However, levels of DR4, DR5, and decoy receptors fail to explain all
cases of sensitivity or resistance. For example, some studies suggested that the ratio of
expression of DR4/5 and decoy receptors determine TRAIL sensitivity (Pan, Ni et al. 1997;
Sheridan, Marsters et al. 1997; Kim, Fisher et al. 2000; Ichikawa, Liu et al. 2001; Wang, Engels
et al. 2004), but this ratio did not correlate with the sensitivity of hepatocytes to TRAIL (Jo, Kim
et al. 2000). One study of melanoma cell lines reported a TRAIL-resistant line expressing
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mRNA for DR5 but not for DcR1 and DcR2 and three TRAIL-sensitive lines expressing DcR1,
DcR2, or both (Griffith, Wiley et al. 1999). Another study of 18 neuroblastoma cell lines found
five that were sensitive to TRAIL but nevertheless expressed DcR1, DcR2, or both (Eggert,
Grotzer et al. 2001). Components of the DISC can also play a role in TRAIL resistance. Several
types of cancer cells show resistance to TRAIL that correlates with down-regulation or absence
of C8 expression (Teitz, Wei et al. 2000; Eggert, Grotzer et al. 2001; Fulda, Kufer et al. 2001;
Hopkins-Donaldson, Ziegler et al. 2003; Yang, Merchant et al. 2003). FLIP expression and the
C8:FLIP ratio have been reported to correlate with TRAIL resistance in several different tumors,
including melanoma, hepatocellular carcinoma, Burkitt's lymphoma, and B-cell chronic
lymphocytic leukemia (Tepper and Seldin 1999; Okano, Shiraki et al. 2003). Lastly,
downstream factors that are not unique to receptor-mediated apoptosis have also been implicated
in TRAIL resistance. These include Bcl-xL and IAPs (Hinz, Trauzold et al. 2000; Zhang, Zhang
et al. 2001; Ng and Bonavida 2002; Ng, Zisman et al. 2002), as well as survival signaling
through NF-KB and the MAP kinase pathway (Zhang and Fang 2005). When considered
together, these studies reveal that the selectivity of TRAIL is much more complex than originally
thought, as each apparently critical factor is defeated by a few cell lines that break the proposed
rule. Single-gene explanations are not likely to explain sensitivity to death-inducing agents as all
of these proteins play a role to a greater or lesser extent depending on their concentrations and
other aspects of cell physiology. A systems-level measurement should have better success at
predicting TRAIL sensitivity.
The capacity of TRAIL to trigger apoptosis preferentially in cancer cells has motivated
the development of several TRAIL-related cancer therapies, which are currently in Phase I and
Phase II clinical trials. Amgen and Genentech have co-developed a recombinant TRAIL;
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Amgen, Genentech, and Human Genome Sciences have separately developed monoclonal
antibodies to DR5 (AMG 655, apomab, and lexatumumab, respectively); Human Genome
Sciences has developed a monoclonal antibody targeting DR4 (mapatumumab) (Ashkenazi and
Herbst 2008). In general, Phase I trials have established that these TRAIL receptor agonists are
well-tolerated in patients. Phase II trials are currently evaluating the therapeutic benefit of these
drugs as single agents or in combination with other targeted cancer therapies such as bortezomib
(a proteosome inhibitor), rituximab (monoclonal antibody against CD20), and bevacizumab
(monoclonal antibody against vascular endothelial growth factor) (Ashkenazi and Herbst 2008).
TRAIL receptor agonists can synergize with other drugs to kill TRAIL-resistant cells in
vitro, perhaps by reducing the heterogeneity in TRAIL-resistant cells to obtain a more complete
response. One attempt involves stimulation of the TRAIL pathway with a DNA damaging agent
to activate the p53 response. Other efforts involve inhibition of survival pathways such as the
NF-iB pathway or the PI3K-Akt pathway, both of which connect to the TRAIL signaling
network. Although numerous studies have measured upregulation of pro-apoptotic factors or
downregulation anti-apoptotic factors during combination treatment, there is little consensus as
to how different chemotherapies synergize with TRAIL (Johnstone, Frew et al. 2008). Efforts to
understand the molecular mechanisms of this synergy would benefit from a dynamic systems-
level approach; Chapter 4 touches on one such effort.
1.3.4 Monitoring the dynamics of apoptotic events in single cells
Apoptosis is a dynamic process whose reaction rates are critical to understanding the
design principles of the apoptotic network as well as cells' sensitivity or resistance to death.
Biochemical assays that involve lysing a population of cells at a single time point obscure the
heterogeneity in the apoptotic response of individual cells, as the contents of both living and
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dead cells are measured in aggregate. Quantifying and predicting the sensitivity or resistance of
normal cells as well as different cancer cell types is essential for clinical studies of TRAIL and
other chemotherapies. The fraction of dead cells at a certain time and the final fraction of
surviving cells are related to the rate at which cells die (S.L.S., unpublished observations). The
molecular mechanisms behind these relationships can best be gleaned by live-cell imaging with
reporters of apoptotic events.
Previous work using live-cell reporters of apoptosis found that cytochrome c and Smac
release from the mitochondria during MOMP is always a rapid, all-or-nothing event (requiring
-10 minutes); this event precedes rapid, all-or-nothing caspase-3 activation by 10-15 minutes
(Goldstein, Waterhouse et al. 2000; Tyas, Brophy et al. 2000; Rehm, Dussmann et al. 2002;
Rehm, Dussmann et al. 2003; Goldstein, Munoz-Pinedo et al. 2005; Munoz-Pinedo, Guio-
Carrion et al. 2006). Much less is known, however, about the pre-MOMP period, which is quite
variable and can last between 0.5 and 12 hours in individual cells undergoing the same treatment.
As MOMP is a binary uni-directional event, the pre-MOMP decision phase must involve the
building toward some threshold of pro-apoptotic signaling which must be crossed in order to
trigger MOMP.
Recent work from our group involved building and making use of live-cell reporters to
understand the network logic linking initiator caspase activation to MOMP and subsequent
effector caspase activation (Albeck, Burke et al. 2008a). The authors used Firster resonance
energy transfer (FRET) to build sensors for caspase activation by linking CFP to YFP with
amino acids selective for initiator (IC-RP) or effector (EC-RP) caspase cleavage sites. A
reporter for MOMP was built by fusing a red fluorescent protein (RFP) to the mitochondrial
import sequence of Smac; this reporter is biochemically inactive as it lacks an IAP-binding
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motif. Using combinations of these reporters, the authors found that initiator caspase activity,
but not effector caspase activity, is present during the pre-MOMP delay (Fig. 1.4). Combining
mathematical modeling with perturbation (over-expression or siRNA) of the network proteins
revealed that XIAP's inhibitory activity of effector caspases is critical for restraining effector
caspase activity during the pre-MOMP delay. This result was experimentally validated by
knocking down XIAP levels (to reduce its ability to restrain effector caspases) and by over-
expressing Bcl-2 or knocking down Bid (to block MOMP). Under these conditions, the pre-
MOMP delay in effector caspase activation was eliminated - instead of being an all-or-nothing
switch, effector caspase activity began to rise slowly soon after TRAIL addition. The possible
consequences of partial effector caspase substrate cleavage in cells that eventually survive
include partial genome and proteome degradation, which have the potential to produce
genomically unstable pre-cancerous cells.
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Figure 1.4. A composite picture of effector and initiator caspases in single cells, a, b, Time courses of cells
expressing IMS-RP and either EC-RP (a) or IC-RP (b), treated with 50 ng/ml TRAIL and 2.5 ug/ml cyclohexi-
mide. Fifty individual cells are shown for each reporter (gray lines), with three cells exhibiting early, late, or
intermediate times of death highlighted in red, blue, and green; vertical bars indicate the time of IMS-RP
release for each highlighted cell. Reprinted from Mol Cell, 30(1), Albeck JG, Burke JM, Aldridge BB, Zhang
M, Lauffenburger DA, Sorger PK. "Quantitative analysis of pathways controlling extrinsic apoptosis in single
cells", 11-25, (2008), with permission from Elsevier.
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A second study from the Sorger laboratory examined the unusual variable delay, snap-
action switch involved in receptor-mediated apoptosis (Albeck, Burke et al. 2008b). This
involved building a differential equation model of the pathway summarized in Fig 1.3, which
was manually calibrated to single-cell experimental data to accurately reproduce the behavior of
normal and perturbed cells. The model describes a single cell's trajectory through the pathway
upon TRAIL stimulation and contains 58 species (18 having non-zero initial conditions and 40
additional species representing cleaved, complexed, or differentially localized forms of the initial
species) which interact via 28 reactions described by 70 rate constants. The authors found that
MOMP is the point at which the graded TRAIL - C8 activation - active Bax signal is converted
to a snap-action response. By building multiple miniature models of the switch with increasing
realism and complexity, the authors found that simple competitive binding between an activator
(active Bax) and an inhibitor (Bcl-2) is not sufficient to create a snap-action switch under any set
of realistic biophysical assumptions. Rather, switch-like behavior requires additional Bcl-2
family members, physical separation of Smac and cytochrome c from their binding partners in
the cytosol, and multimerization of Bax into functional complexes. When pores finally form,
Smac and cytochrome c are rapidly release due to the very steep concentration gradient involved
in moving these proteins from the mitochondrial inter-membrane space to the cytosol. In
summary, transition from graded to switch-like kinetics was found to be a result of maintenance
of a very tight "off' state during the pre-MOMP delay followed by a low impedence "on" state.
In all of these single-cell studies of apoptosis, cell-to-cell variability in various apoptotic
events is noticeable, but the origins of this variability and the possible physiological
consequences are not addressed. The building of the live-cell reporters and mathematical model
described above as well as the detailing of the network features responsible for certain
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characteristics of apoptotic cell death laid the foundation for this thesis, which addresses the
origins and consequences of cell-to-cell variability in apoptosis.
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Chapter 2
2 Non-genetic origins of cell-to-cell variability in
TRAIL-induced apoptosis
This chapter is based upon:
Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis
Nature, Advanced online publication, Epub Date 12 April 2009
DOI: 10.1038/nature08012
Sabrina L. Spencer*, Suzanne Gaudet*, John G. Albeck, John M. Burke, Peter K. Sorger
(* These authors contributed equally to this work.)
In microorganisms, noise in gene expression gives rise to cell-to-cell variability in protein
concentrations (McAdams and Arkin 1997; Elowitz, Levine et al. 2002; Ozbudak, Thattai et al.
2002; Blake, M et al. 2003; Colman-Lerner, Gordon et al. 2005; Golding, Paulsson et al. 2005;
Rosenfeld, Young et al. 2005). In mammalian cells, protein levels also vary (Sigal, Milo et al.
2006; Chang, Hemberg et al. 2008; Feinerman, Veiga et al. 2008) and individual cells differ
widely in responsiveness to uniform physiological stimuli (Goldstein, Kluck et al. 2000; Lahav,
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Rosenfeld et al. 2004; Geva-Zatorsky, Rosenfeld et al. 2006; Albeck, Burke et al. 2008a; Albeck,
Burke et al. 2008b). In the case of apoptosis mediated by TRAIL (TNF related apoptosis-
inducing ligand) it is common for some cells in a clonal population to die while others survive -
a striking divergence in cell fate. Among cells that die, the time between TRAIL exposure and
caspase activation is highly variable. Here we image sister cells expressing reporters of caspase
activation and mitochondrial outer membrane permeabilisation (MOMP) following exposure to
TRAIL. We show that naturally occurring differences in the levels or states of proteins
regulating receptor-mediated apoptosis are the primary causes of cell-to-cell variability in the
timing and probability of death. Protein state is transmitted from mother to daughter, giving rise
to transient heritability in fate, but protein synthesis promotes rapid divergence so that sister cells
soon become no more similar to each other than pairs of cells chosen at random. Our results
have implications for understanding "fractional killing" of tumor cells following exposure to
chemotherapy, and for variability in mammalian signal transduction in general.
2.1 Results
TRAIL elicits a heterogeneous phenotypic response in both sensitive and relatively
resistant cell lines: some cells die within 45 min, others 8-12 hr later, and yet others live
indefinitely (Supplementary Fig. 2.1). During the variable delay between TRAIL addition and
MOMP, upstream initiator caspases are active but downstream effector caspases are not (Albeck,
Burke et al. 2008a; Albeck, Burke et al. 2008b). Possible sources of cell-to-cell variability in
responses to TRAIL include genetic or epigenetic differences, stochastic fluctuations in
biochemical reactions involving low copy number components ("intrinsic noise" (Elowitz,
Levine et al. 2002)), differences in cell cycle phase, and natural variation in the concentrations of
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key reactants. To distinguish among these and other possibilities, we used live-cell microscopy
to compare the timing and probability of death in sister cells exposed to TRAIL. Were
phenotypic variability caused by genetic or epigenetic differences, sister cells should behave
identically. In contrast, were stochastic fluctuations in reactions triggered by TRAIL to
predominate, sister cells should be no more similar to each other than pairs of cells selected at
random. The influence of cell cycle state on apoptosis should be readily observable from time-
lapse imaging of asynchronous cultures. Finally, variability arising from differences in protein
levels (or in activity or modification state) should produce a highly distinctive form of
inheritance in which newly born sister cells are very similar, because they inherit similar
numbers of abundant factors from their mother (Golding, Paulsson et al. 2005; Rosenfeld, Young
et al. 2005), but then diverge as new proteins are made and levels drift (Sigal, Milo et al. 2006;
'Kaufmann, Yang et al. 2007). With this in mind, we examined apoptosis in HeLa cells and in
non-transformed MCF10A mammary epithelial cells in the presence and absence of protein
synthesis inhibitors.
Pairs of sister cells expressing a fluorescent reporter of MOMP (IMS-RP; (Albeck, Burke
et al. 2008a)) born during a 20-30 hr period were identified by time-lapse microscopy. TRAIL
and the protein synthesis inhibitor cycloheximide were then added and filming continued for
another 8 hr. The TRAIL to MOMP interval (Td) was calculated for each cell (Fig. 2.1a).
Among recently divided sisters (< 7 hr between division and death), Td was highly correlated (R2
= 0.93, Fig. 2.1b) whereas Td was uncorrelated (R2 = 0.04) for recently divided cells chosen at
random. Time since division (Fig. 2.1c) and position in the dish (data not shown) did not
correlate with Td, ruling out a role for cycle state and cell-cell interactions under our
experimental conditions. However, as time since division increased, sister-to-sister correlation in
-39-
Td decayed exponentially with a half-life of -11 hr so that sisters lost memory of shared ancestry
within 50 hours or about 2 cell generations (R2 < 0.05, the same as random pairs of cells; Fig.
2.1 d,e). Similar results were obtained with MCF10A cells (Supplementary Fig. 2.2).
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Figure 2.1. Time-to-death is highly correlated between HeLa sister cells but correlation decays as a function of
time since division. a, Schematic of experimental design. ATd represents the difference in time of MOMP
between sisters; T(Div-+MOMP) the time between cytokinesis of the mother and the average time of MOMP
in daughter cells; T(Div-+Stim) the time between cytokinesis and TRAIL addition. The shading of each cell
depicts concentrations/states of relevant proteins. b and f, Similarity in Td among pairs of recently divided sister
cells ( T(Div-*MOMP) " < 7 hr for (b) and <3.5 hr for (f)). c and g, Td as a function of T(Div--Stim), a proxy for
cell cycle state (R2 < 0.03). d and h, ATd as a function of T(Div- MOMP) . e and i, Decay in the correlation of
Td between sister pairs as a function of T(Div-*MOMP) . In (i), black circes represent data for cells treated
with TRAIL plus cycloheximide imaged in parallel with the TRAIL alone treatment (Supplementary Fig. 2.5).
High correlation among recently born sisters shows that variability in Td arises from
differences that exist prior to TRAIL exposure and rules out stochastic fluctuations in signaling
reactions. Rapid decorrelation also rules out genetic mutation or conventional epigenetic
differences (which typically last 10-105 cell divisions (Rando and Verstrepen 2007)). However,
transient heritability is precisely what we expected for cell-to-cell differences arising from
variations in the concentrations or states of proteins that are partitioned binomially at cell
division.
Whereas all TRAIL-treated HeLa cells eventually died in the presence of cyloheximide,
in its absence a fraction always survived (presumably due to induction of survival pathways
(Chaudhary, Eby et al. 1997)). When the fates of sister cells were compared, both lived or both
died in almost all cases (chi-square test, p=7x10-19, Supplementary Fig. 2.3). Variability in Td
across the population was large (Fig. 2.1g and Supplementary Fig. 2.4), but recently born sisters
were nevertheless correlated in Td (R2=0.75, Fig. 2.1f). Again, cell cycle phase was not
correlated with fate or time-to-death (Fig. 2.1 g). Decorrelation in Td among sisters was an order
of magnitude more rapid in the presence of protein synthesis than in its absence (-1.5 hr half-
life, Fig. 2. 1h,i and Supplementary Fig. 2.5). Thus, the length of time that Td is heritable is very
sensitive to rates of protein synthesis, both basal and TRAIL-induced.
Are the concentrations of proteins regulating TRAIL-induced apoptosis sufficiently
different from cell to cell to account for variability in Td? Using flow cytometry, we measured
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the distributions of five apoptotic regulators for which specific antibodies are available. All five
proteins were log-normally distributed across the population with coefficients of variation
between 0.21 and 0.28 for cells of similar size (Fig. 2.2a), consistent with data on other proteins
(Sigal, Milo et al. 2006). To determine the impact of variability in protein levels on variability in
time-to-death, we turned to an ordinary differential equation model of TRAIL-induced apoptosis
(Albeck, Burke et al. 2008b). This model encapsulates the biochemistry of TRAIL-mediated
death and recapitulates the dynamics of apoptosis under various conditions of protein depletion
or over-expression (Albeck, Burke et al. 2008b). When variability in Td arising from variance in
protein levels was modeled, a good match was observed to experimental data (Fig. 2.2b-d)
implying that measured differences in protein levels are sufficient to account for variability in Td.
a b CExperiment Simulation
2000
25 250 ng/mil
20 50 ng/rmi 1608 10 ng/mi
A _' 1200
/ J 4 XIAP 
Bax 0 10
0 Bcl-2 5
S 7 BC3 5
3 Bid 0
d
T
death?
during,
I9 6 .-I 0 800400 -__
( 0 2 4 6 8 10 12 -0 2 4 6 8 10 12
Td (hr) Td (hr)
Coefficients of variation in Td Figure 2.2. Endogenous variation in the concentrations of apoptotic
RAIL dose Experiment Simulation regulators is sufficient to explain variability in Td. a, Protein distributionsin untreated HeLa cells determined by flow cytometry. b and c, Distribu-
10 ng/ml 0.24 0.21 tions of T. for HeLa cells treated with TRAIL at concentrations indicated
50 ng/ml 0.18 0.23 (with cyloheximide) as determined experimentally (b) or estimated by
250 ng/ml 0.21 0.25 simulations (c). d, Coefficients of variation for distributions in (b) and (c).
Which steps in receptor-mediated apoptosis are responsible for variation in time-to-
To address this question, we grouped reactions into three sets: those occurring before,
or subsequent to MOMP (Fig. 2.3a - blue, grey, and orange). Before MOMP, TRAIL
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binds and oligomerizes DR4/5 receptors, promoting assembly of death-inducing signaling
complexes (DISCs) that then activate initiator pro-caspases-8 and -10 (C8/10) (Fuentes-Prior and
Salvesen 2004). Active C8/10 cleaves Bid to tBid (Li, Zhu et al. 1998; Luo, Budihardjo et al.
1998), which activates the pore-forming proteins Bax and Bak (Youle and Strasser 2008). C8/10
also processes effector pro-caspases-3 and -7 (C3/7) but C3/7 activity is held in check by XIAP
until MOMP (Fuentes-Prior and Salvesen 2004). MOMP itself involves self-assembly of
activated Bax/Bak into transmembrane pores, a process antagonized by anti-apoptotic Bcl-2
proteins (Youle and Strasser 2008). When levels of activated tBid, Bax, and Bak exceed a
threshold set by inhibitory Bcl-2 proteins, pores form in the mitochondrial outer membrane,
allowing cytochrome c and Smac to translocate into the cytosol (Youle and Strasser 2008). In
post-MOMP reactions, cytosolic Smac neutralizes XIAP, relieving C3/7 inhibition and allowing
cleavage of effector caspase substrates and consequent cell death (Fuentes-Prior and Salvesen
2004). In a parallel route to C3/C7 activation, cytosolic cytochrome c promotes apoptosome
assembly and caspase-9 activation.
To determine which steps in TRAIL-induced apoptosis play the greatest role in
determining variability in death time, we imaged cells expressing a reporter of either initiator or
effector caspase activity (IC-RP or EC-RP) (Albeck, Burke et al. 2008a) in combination with
IMS-RP. We found almost all variability in Td to arise during the pre-MOMP interval (Fig.
2.3b). The timing of MOMP itself is determined by the rate at which tBid accumulates to a
threshold set by the levels of Bcl-2 family proteins. This rate and threshold can be determined
from the initial rate of IC-RP cleavage (kic) and the fraction of IC-RP cleaved (0) at the time of
MOMP, respectively. When kic and 0 were measured in single TRAIL-treated cells, the timing
of MOMP was found to be controlled by a variable rate of approach to a threshold of variable
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height (Fig. 2.3c,d). However, variation in kic played a significantly greater role in determining
Td than variation in 0 (R2=0.82 vs. R2=0.22; Fig. 2.3e,f, and Supplementary Fig. 2.7). Moreover,
kic was very similar in recently born sister cells with similar Td, but dissimilar in older sisters
(Fig. 2.3g). We conclude that cell-to-cell variability in kic - and by implication the rate of
conversion of Bid to tBid - is the primary determinant of variability in time-to-death under our
experimental conditions.
Levels of multiple proteins set kc, including DR4/5 receptors, DISC components, C8,
and Bid itself. Modelling suggested that knowing the concentration of any single protein
upstream of Bid would have minimal value in predicting Td - the impact of variation in all other
proteins is too great (Fig. 2.4a). Live-cell analysis of FLIP, an important regulator of pro-
caspase-8 binding to the DISC, was consistent with this prediction, as was analysis of other
single proteins by flow cytometry (Fig. 2.4b and data not shown). However, modelling showed
that with increasing over-production of Bid, measurement of its levels would be increasingly
predictive of Td (Fig. 2.4c, Supplementary Fig. 2.8). We therefore measured the relationship
between dispersion in Td and levels of Bid-GFP (Fig. 2.4d). A -50-fold increase in Bid-GFP
caused the variability in Td to fall significantly, concomitant with a decrease in mean time-to-
death from -3 hr to -45 min. Thus, only when over-expressed is the level of one protein
predictive of Td; under normal circumstances, control is multivariate.
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Figure 2.3. A single time-dependent process upstream of MOMP predicts time-to-death. a, Schematic of
receptor-mediated apoptosis signalling with IC-RP, EC-RP, and IMS-RP indicated. The Bcl-2 protein family is
represented in simplified form by Bid, Bax, and Bcl-2. Reactions occur before (blue), during (grey), or
subsequent to MOMP (orange). b, Timing of apoptotic events in HeLa cells expressing IMS-RP and EC-RP
and treated with TRAIL; blue-grey denotes the pre-MOMP interval and orange the interval between MOMP
and half-maximal cleavage of EC-RP (a marker of death). Insets show death times computed from data
(top) and contributions of pre-MOMP (middle) or post-MOMP (top) intervals. c and d, Raw and fitted trajec-
tories for IC-RP cleavage in single TRAIL-treated HeLa cells co-expressing IMS-RP and IC-RP. Values for
height of the MOMP threshold (9) and rate of approach to the threshold (kc) were derived by fitting
(Supplementary Fig. 2.6). e, Correlation between Td and kc (left) or 8 (right) for data in (d). f, Relative
contributions of variability in kc (blue) or 0 (grey) to variability in Td (black; Supplementary Fig. 2.7). g,
Trajectories of IC-RP cleavage in recently divided sister HeLa cells having similar Td (red) and older sisters
with differing Td (black) treated with 50 ng/ml TRAIL.
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Figure 2.4. No single protein predicts Td under normal conditions but over-expression
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simulated cell. b, Death time as a function of endogenous FLIP levels in H1299 cells.
c and d, Effect of GFP-Bid over-expression on Td in HeLa cells, as predicted by
simulation (c) or observed in experiment (d). Inset shows reduction in dispersion of Tdwith increasing Bid, as measured by interquartile range (IQR; Supplementary Fig. 2.8).
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2.2 Discussion
Other studies (for example, ref. (Wagner, Punnoose et al. 2007)) address genetic factors
determining the average sensitivity of cell lines to TRAIL whereas this paper examines non-
genetic cell-to-cell variability within an individual cell line. We come to three primary
conclusions. First, cell-to-cell variation in the timing and probability of death is transiently
heritable. Cell cycle state, number of neighbouring cells, and stochastic fluctuations in TRAIL-
induced signalling reactions do not play a major role under our conditions. Instead, variability in
phenotype arises from cell-to-cell differences in protein levels that exist prior to TRAIL
exposure (our experiments do not distinguish between cell-to-cell differences in total
concentrations or in post-translationally modified forms). Second, the rate at which sisters lose
memory of a shared past is an order of magnitude faster in the presence of protein translation
than in its absence. This further implicates variability in protein levels as the origin of
differences in phenotype. Third, knowing the concentration of individual proteins does not allow
Td to be predicted but measuring the rate of a single reaction does (Bid to tBid conversion in our
experiments). These findings are likely to hold for other examples of ligand-induced apoptosis,
however for intrinsic apoptosis, different proteins will control the rate of approach to MOMP and
0 may dominate in certain contexts. Moreover, given the prevalence of multi-protein cascades in
signal transduction, multivariate control over cell-to-cell variability is likely to be more common
than the univariate control observed in other settings (Wagner, Punnoose et al. 2007; Chang,
Hemberg et al. 2008; Cohen, Geva-Zatorsky et al. 2008).
Heritable, non-genetic determinants of phenotype are often referred to as "epigenetic"
(Rando and Verstrepen 2007), but the transient heritability we observe is fundamentally different
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in origin and duration. Given variability in growth rates and noise in gene expression,
genetically identical cells will inevitably contain slightly different concentrations of most
proteins. However, differences in protein concentrations do not necessarily affect phenotype, a
property often referred to as robustness (Barkai and Leibler 1997). For example, the efficiency
with which effector caspase substrates are cleaved does not vary from cell to cell (Albeck, Burke
et al. 2008b). Given the importance of tight control over apoptosis, cell-to-cell variability in the
timing and probability of death seems unlikely to reflect an inability of cells to achieve robust
regulation. Instead, by transforming what is a binary decision at the single-cell level into a
graded response at the population level, variability probably has an adaptive advantage. TRAIL
is currently undergoing clinical trials as an anti-cancer drug (Ashkenazi and Herbst 2008) and
our findings may have implications for the use of TRAIL and other apoptosis inducers as
therapeutics. Many drugs exhibit "fractional killing" in which each round of therapy kills some
but not all of the cells in a tumor (Berenbaum 1972). Traditionally, this is thought to reflect
differences in genotype, cell cycle state, or the involvement of cancer stem cells, but our data
demonstrate that dramatic variability can also arise from natural differences in protein levels.
We propose that the efficiency of TRAIL-mediated killing of cancer cells could be increased by
reducing the impact of cell-to-cell variability, perhaps through co-drugging.
2.3 Methods
2.3.1 Methods summary
Live-cell microscopy. Cells expressing IMS-RP and FRET reporters EC-RP or IC-RP
were imaged as described (Albeck, Burke et al. 2008a). In Figure 2.1, cells were imaged for 20-
30hr to determine time of division and identify sisters; then media containing 50 ng/ml TRAIL
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plus 2.5 ptg/ml cycloheximide or 250 ng/ml TRAIL alone was added. The difference in TRAIL
concentrations was designed to generate a similar range in Td with and without cycloheximide
(Supplementary Fig. 2.4). Cells were then imaged for 8 hr to determine the time of MOMP, by
monitoring cytosolic translocation of IMS-RP. Unless otherwise noted, all treatments included
2.5 jtg/ml cycloheximide.
Data analysis. Correlation coefficients (R2) were obtained by linear regression except
where noted. Sister-sister correlation was determined by sorting pairs of cells on
T(Div -+ MOMP)avg and calculating R2 for the first 40 pairs. R2 was then re-calculated for cells
2-41, 3-42, etc., and the results plotted as a function of the average T(Div - MOMP)avg for the
40 cells in question, denoted by "< >". The results were fit to an exponential decay:
R 2 = 1.2e ( - 0.063T(Div-MOMP) ,,g) for TRAIL plus cycloheximide, and R 2 = 2 .3e ( - 0.4 7 T(Div->MOMP) , ) for
TRAIL alone. Half-lives were calculated as ln(2)/0.063 = 11 hr, and ln(2)/0.47 = 1.5 hr.
Contributions to Td of kic, 0, and pre- and post-MOMP intervals were obtained by fixing one
parameter and allowing the other to vary over the observed range, then mean-centring the
resulting distributions (Supplementary Fig. 2.7). Fitted IC-RP trajectories were obtained after
subtracting a trajectory for cycloheximide alone (Fig. 2.3c) to control for photobleaching
(Supplementary Fig. 2.6).
Modelling. The responses of cell populations were simulated using a trained ODE model
(Albeck, Burke et al. 2008b) sampling from log-normally distributed protein concentrations with
CVt0.25 (see Supplemental Methods). In Figure 2.4, GFP-Bid (an experimental observable)
was added to log-normally distributed endogenous Bid (unobservable); other proteins were
sampled from lognormal distributions as before: Simulations were adjusted to match the
distribution GFP-Bid achieved experimentally.
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2.3.2 Supplementary methods
Cell culture and transfections. HeLa cells were maintained in DMEM (Mediatech, Inc.)
supplemented with L-glutamine (Gibco), penicillin/streptomycin (Gibco) and 10% foetal bovine
serum (Mediatech, Inc.). MCF10OA cells were cultured as described(Debnath, Muthuswamy et
al. 2003). H1299 cells containing FLIP tagged with YFP at the endogenous locus were obtained
from the Kahn Dynamic Proteomics Project and maintained at 8% CO 2 in RPMI (Mediatech,
Inc.) with 10% foetal bovine serum and penicillin/streptomycin. HeLa cells expressing IMS-RP
(Albeck, Burke et al. 2008a) were transfected using FuGENE 6 (Roche) with pd4-Bid-EGFP
(Clontech) to sample expression levels across a wide range. H1666 cells were maintained (and
imaged) in RPMI supplemented with 10% FBS, L-Glutamine, penicillin/streptomycin, lx ITES
(Lonza Biosciences #17-839Z), 50 nM hydrocortisone, 10 uM phosphorylethanolamine, 0.1 nM
Tri-iodothyronine, 10 mM HEPES, 0.5 mM sodium pyruvate, 2 g/L BSA, and 1 ng/mL EGF.
Fresh primary liver cells were obtained from CellzDirect and plated on collagen type I. Cells
were maintained (and imaged) in Eagle's Minimum Essential Medium supplemented with 10%
FBS, L-Glutamine, 100 nM dexamethasone, 5 ug/mL human insulin, 5 ug/mL transferrin from
human serum, 5 ug/mL sodium selenite, and 15 mM HEPES. SKBR3 cells were maintained
(and imaged) in RPMI supplemented with 10% FBS, L-Glutamine, and penicillin/streptomycin.
Live-cell microscopy. HeLa cells expressing IMS-RP and FRET reporters EC-RP or IC-
RP were imaged in a 37°C humidified chamber as described (Albeck, Burke et al. 2008a). For
sister cell experiments, HeLa cells expressing IMS-RP were imaged (Albeck, Burke et al. 2008a)
at 10-minute intervals for 20-30 hours in phenol red-free CO 2 independent medium (Invitrogen)
with L-glutamine, penicillin/streptomycin, and 1% serum (Fig. 2.1b-e) or at -5% CO 2 in phenol
red-free DMEM with L-glutamine, penicillin/streptomycin, and 10% serum (Fig. 2.1f-i, see also
Supplementary Fig. 2.5). The growth media was then replaced with the same media containing
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TRAIL (Alexis Biochemicals ALX-201-115) with or without 2.5 ptg/ml cycloheximide (Sigma-
Aldrich) and images were acquired at 3-minute intervals for an additional 8 hr. Cells still alive at
the end of the 8 hr were considered to have survived the treatment. MFC10A were imaged as
described (Albeck, Burke et al. 2008a) but in -5% CO 2 in phenol red-free assay media (Debnath,
Muthuswamy et al. 2003) without EGF or insulin to reduce cell migration. HeLa cells co-
expressing IMS-RP and Bid-GFP and H1299 YFP-FLIP cells were imaged (Albeck, Burke et al.
2008a) in the same media as described above for Fig. 2.1b-e but at 20x magnification with
frames every 3 min or every 10 minutes, respectively. H1666, SKBR3, and primary liver cells
were imaged in 96-well glass bottom plates (Matrical) on a Nikon TE2000E at 10x
magnification in a 370 C chamber with 5% CO2.
Image analysis. Sister-cell tracking was performed manually. To assess whether there
is a cell cycle effect on death time, we plotted death time as a function of time since division, as
a proxy for cell cycle phase. Because the distribution of time since division is not uniform, one
might infer a cell cycle effect but, in fact, a cell cycle effect would appear as a slope in the data,
which we do not observe. For sister cell experiments where CO2 independent medium was used,
there was more proliferation early in the divisions movie (and thus more points near "G2")
because CO2 independent medium does not support very long term proliferation (division slows
down, but the cells are not dying). Importantly, the lack of cell cycle effect is also apparent for
sister cell experiments performed in DMEM, the standard medium for HeLa cells
(Supplementary Fig. 2.5). In these experiments, the cells proliferated continuously during the
divisions movie. Cells that divided early in the divisions movie often divided again if they
survived stimulation with TRAIL, producing "cousins" which were excluded from the analysis.
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This resulted in fewer cells in the "G2" region, but this does not indicate a cell cycle effect, as
the probability of surviving or dying is constant.
Analysis of IC-RP and EC-RP cleavage and IMS-RP translocation was performed as
described (Albeck, Burke et al. 2008a). To derive estimates for kc and 0, individual cell
trajectories were fit with an equation derived from mathematical reduction of the differential
equation model for the pathway (J.M.B., J.G.A, S.L.S., D. Lauffenburger, P.K.S., manuscript in
preparation; see also Supplementary Fig. 2.5). The equations for the fitted relationship between
Td and kc and between Td and 0 were as follows: Td =6.9e(-53.7 klC) and Td =6.8 0 +1.1 . FLIP-
YFP fluorescence was quantified at t = 0 hr (time of TRAIL addition) by manually outlining the
cell and measuring the average fluorescence intensity within the outline. For FLIP-YFP cells,
time of death was scored as the first frame where a cell exhibited apoptotic morphology. Bid-
GFP fluorescence was quantified at t = 0 hr by measuring the average fluorescence intensity
from a representative area within the cell. To determine the absolute number of proteins/cell, the
average Bid-GFP fluorescence intensity from these movies was set equal to the average number
of GFP-tagged proteins per cell as measured by quantitative immunoblot Supplementary Fig.
2.9).
Flow cytometry. The distributions of initial protein levels were measured in HeLa cells
(fixed with paraformaldehyde and permeabilised with methanol) on a FACSCalibur (BD
Biosciences). The antibodies were carefully validated by knockout or knockdown and/or by
over-expression of GFP-tagged fusion proteins. The following antibodies were used: a-Bid
(HPA000722, Atlas Antibodies), a-Bax (MAB4601, Chemicon International), a-Bcl-2 (SC7382,
Santa Cruz Biotechnology), a-XIAP (610717, BD Biosciences), a-C3 (SC7272, Santa Cruz
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Biotechnology). The coefficient of variation (CV) of cells of similar size (as estimated by
forward scatter) ranged from 0.21 to 0.28.
Modelling. The details of methods used will be described elsewhere. Briefly, a series of
104 simulations of the EARMvl1.1 ordinary differential equation model (Albeck, Burke et al.
2008b) (modified to include general protein synthesis and degradation) were run in Jacobian
(Numerica Technology). In previous work, only single values for each protein concentration
were used (Albeck, Burke et al. 2008b). Here, for each run of the model (representing one cell),
initial protein levels were independently sampled from log-normal distributions having mean
values identical to those previously reported (Albeck, Burke et al. 2008b) (except for Bcl-2,
whose mean was set to 30,000 molecules/cell), and coefficient of variation as measured by flow
cytometry (Fig. 2.2a) or set to 0.25 for proteins that were not measured. Initial protein
concentrations and parameter values are listed in Supplementary Tables 1 and 2.
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2.4 Supplementary figures
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Supplementary Figure 2.1. Variability in death time with and without cycloheximide.The three cell
types indicated were treated with 50 ng/ml TRAIL alone (top panels) or 50 ng/ml TRAIL + cycloheximide
bottom panels) and imaged by brightfield microscopy every 10 minutes for 25.5 hr. One hundred cells
were analyzed for each distribution. Death time was scored as the first frame of apoptotic morphology.
Cells surviving this 25.5 hr movie are labeled with an "S" and the percentage of survivors is indicated.
H1666 cells were the most sensitive line examined, while SK-BR-3 cells were the most resistant.
However, even H1666 show variability in cell fate when treated with TRAIL alone. Cumulative count
was calculated from the distributions.
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Supplementary Figure 2.2. Time of MOMP is correlated in sister MCF10A cells
treated with TRAIL + CHX. The fluorescent reporter for MOMP (IMS-RP) was introduced into
MCF1OA cells. Cells were imaged with at 10x magnification for 28 hr (frames every 10 min) to
determine division times and track pairs of sister cells. Subsequently, the growth media was
replaced with media containing 50 ng/ml TRAIL plus 2.5 pg/ml cycloheximide and cells were
imaged (frames every 4 min) until all had died. a, Correlation in death time (Td) between 40
pairs of recently divided sister cells (T(Div-,- MOMP),< 15.4 hr). Each circle denotes a
pair of sister cells. The correlation coefficient (R2) was obtained by linear regression. b, Differ-
ence in Tdof sister cell pairs (ATd) as a function of T(Div--* MOMP)..
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Number of cells that died: 360
Number of cells that survived: 240
Total number of cells analyzed: 600
Probability of dying: 0.6
Probability of surviving: 0.4
Fates of sister pairs: Live-Live Live-Die or Die-Live Die-Die
Expected fraction: 0.16 0.48 0.36
Expected number: 48 144 108
Observed number: 86 68 146
Chi 2 value = 83.56
Degrees of freedom = 2
p-value = 7.16 x10 -19
Supplementary Figure 2.3. Cell fate is correlated in sister
HeLa cells treated with TRAIL alone. Table contains sister
cells from the experiment depicted in Fig. 2.1f-i (250 ng/ml TRAIL).
The number of cells that survived the treatment and the number
that died were determined. The probability of surviving and the
probability of dying were computed and used to determine the
expected probability that a random pair of cells would either
both live, both die, or have disparate fates (one lives, one dies).
A Chi2 test was used to compare the expected and observed
numbers of pairs in each category. The highly statistically
significant p-value indicates that sister pairs are much more
likely to share the same fate (both live or both die) than would
be expected for random pairs of cells.
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Supplementary Figure 2.4. Distributions of death time for HeLa sister cells, with and
without cycloheximide. The distributions of MOMP times (Td ) of HeLa cells used for the
sister cell experiments presented in Fig. 2.1 are plotted. a, Cells treated with 50 ng/ml TRAIL plus
cycloheximide (CHX) in CO2 independent medium with 1% serum (for Fig. 2.1 b-e). b, Cells
treated with 250 ng/ml TRAIL in the absence of CHX in DMEM with 10% serum (for Fig. 2.1f-i
and Supplementary Fig. 2.5). c, Cells treated with 10 ng/ml TRAIL plus CHX in DMEM with
10% serum (for Fig. 2.1i and Supplementary Fig. 2.5).
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of time between division and stimulation, a proxy for cell
o0 20 25 cycle phase. Cell cycle phases are ndicated as G1, S, G2,
T(Div-,MOMP)avg (hr) as approximated from time since division. No correlation
d was observed between cell cycle phase and Td (R2 = 0.0008).
1. c, Difference in Td of sister cell pairs (ATd) as a function
of T(Div -+ MOMP)a,,. d, Decay in the correlation of
5 0.8 t2=15 hr sister cells for cells treated without cycloheximide (grey;
A) reproduced from Fig. 2.1i) or with cycloheximide
0.6 (black).
0.4 t.5 hr
0.2
0
T(Div-MOMP)avg (hr)
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Supplementary Figure 2.6. Fitting of IC-RP trajectories. The cell
shown was treated with 50 ng/ml TRAIL plus 2.5 pg/ml CHX and
imaged as described in Methods. For all of the cells in Fig. 2.3c,
background-subtracted CFP and YFP images were divided to create a
ratiometric image using ImageJ and custom plug-ins. For each cell, we
then subtracted the minimum signal value across all time points. The
cell was deemed "dead" at the first decrease in signal following MOMP.
We normalized the trajectory by dividing by the signal's value at this
point. As the cell dies and lifts off the plate, the signal becomes noisy.
We therefore force the signal to a value of one from this point on and fit
to this modified trajectory (blue). To produce the trajectory in Fig. 2.3d,
fitting was performed in MATLAB using the function 'nlinfit' with
the following equation, mathematically derived to represent a single
cell's IC-RP trajectory (J.M.B., J.G.A., S.L.S., D. Lauffenburger, P.K.S.,
manuscript in preparation).
S1 - e-klct3 t < T
y I_ e-kIt'3
- kf(t-)' t>
r corresponds approximately to the time of MOMP. We found kf to be
invariant across dose and thus we focused only on kic in the body of
the text.
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Supplementary Figure 2.7. Contribution of kic vs. 0. For
distributions shown in Fig. 2.3f, the relative contribution of
variability in kc and e to variability in Td was assessed compu-
tationally by fixing one parameter at its mean value, allowing
the other to vary over the observed range, and assessing the
resulting distribution of T, The distributions were then
mean-centered at 0. The effects of the two parameters contribute
non-linearly to time of MOMP.
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"Supplementary Figure 2.8. Computational
analysis suggests that Bid overexpression
reduces Td mean and dispersion. Simula-
tions were performed to mimic overexpression
of GFP-Bid. All initial protein concentrations
were sampled from lognormal distributions as
described in Methods, but an additional
amount of Bid was added (GFP-Bid), by
sampling from a uniform distribution. a, Td
as a function of GFP-Bid amount per cell for
10,000 simulations. b, Average Td plotted as
5 a function of GFP-Bid levels for 15 bins
showing that Bid overexpression reduces
average Td. Error bars represent the inter-
quartile range (75th percentile value - 25th
percentile value). c, Dispersion in the values
of Td as a function of GFP-Bid levels. The
dispersion in the distribution of Td in 15 equal
intervals of GFP-Bid expression was mea-
sured using the interquartile range to mini-
mize the effect of outliers in the distribution.
The variability in Td decreases as GFP-Bid
5 levels increase.
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Supplementary Figure 2.9. Quantitative immuno.
blots for Bid-GFP and endogenous Bid in HeLa
cells. Pure GFP protein (Biovision, #4999-100) and
HeLa cell lysate were separated by 10% Tricine
SDS-PAGE as indicated and transferred to a PVDF
membrane, scanned on a LI-COR Odyssey scan-
ner, and quantified digitally. a, The membrane was
probed with mouse anti-GFP (Roche
#11814460001) followed by IRDye 800-conjugated
anti-mouse. b, From the standard curve, we
calculate that a single IMS-RP Bid-GFP clone 3.1
HeLa cell has 8.51x10-10 g Bid-GFP. Using 27 kDa
as the molecular weight of GFP, we find 19,000
Bid-GFP/cell. c, The membrane was probed with
rabbit anti-Bid (Atlas Antibodies HPA000722)
followed by AF680-conjugated anti-rabbit. Using
the IMS-RP Bid-GFP clone 3.1 HeLa cells as a
standard, we find that a single IMS-RP Bid-GFP
clone 3.4 HeLa cell has 62,000 Bid-GFP/cell. We
set the average (background subtracted) IMS-RP
Bid-GFP clone 3.4 fluorescence intensity (70.9
relative fluorescence units, RFU) of the population
of cells in the first frame of a movie equal to 62,000
(calculated above; 70.9 RFU = 62,000 Bid-
GFP/cell). This allows us to rescale the x-axis of
Fig. 2.4d into units of Bid-GFP proteins per cell.
Finally, using the IMS-RP Bid-GFP clone 3.1 HeLa
cells as a standard and 21,995 as the molecular
weight of Bid, we find 20,000 endogenous Bid/HeLa
cell. The average of 3 such measurements yields
28,000 endogenous Bid/HeLa cell; s.e.m. = 5,000.
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Supplementary Tables
Table 1: Initial conditions and synthesis/degradation rates.
See (Albeck, Burke et al. 2008b) for reaction equations; * indicates a unitless constant.
Initial conditions HeLa Base case Synthesis rate Degradation rate Coefficient
initial condition (molecules/s) (l/s) of variation
(molecules/cell)
1 Ligand 1000* 0 2.9E-6 0
2 Receptor 1000 0.00044 2.9E-6 0.25
3 Ligand:Receptor 0 0 2.9E-6 N/A
4 Receptor* 0 0 2.9E-6 N/A
5 Flip 2000 0.00087 2.9E-6 0.25
6 Flip:Receptor* 0 0 2.9E-6 N/A
7 Caspase-8 10000 0.00435 2.9E-6 0.25
8 Caspase-8:Receptor* 0 0 2.9E-6 N/A
9 Caspase-8* 0 0 2.9E-6 N/A
10 Bar 1000 0.00044 2.9E-6 0.25
11 Caspase-8*:Bar 0 0 2.9E-6 N/A
12 Caspase-3 10000 0.00435 2.9E-6 0.282
13 Caspase-8*:Caspase-3 0 0 2.9E-6 N/A
14 Caspase-3* 0 0 2.9E-6 N/A
15 Caspase-6 10000 0.00435 2.9E-6 0.25
16 Caspase-3*:Caspase-6 0 0 2.9E-6 N/A
17 Caspase-6* 0 0 2.9E-6 N/A
18 Caspase-6*:Caspase-8 0 0 2.9E-6 N/A
19 XIAP 100000 0.04350 2.9E-6 0.288
20 XIAP:Caspase-3* 0 0 2.9E-6 N/A
21 PARP 1000000 0.43500 2.9E-6 0.25
22 Caspase-3*:PARP 0 0 2.9E-6 N/A
23 cPARP 0 0 0 N/A
24 Bid 60000 0.02610 2.9E-6 0.288
25 Caspase-8*:Bid 0 0 2.9E-6 N/A
26 tBid 0 0 2.9E-6 N/A
27 Mcl-1 20000 0.00870 0.0001 0.25
28 tBid:Mcl-1 0 0 2.9E-6 N/A
29 Bax 80000 0.03480 2.9E-6 0.271
30 tBid:Bax 0 0 2.9E-6 N/A
31 Bax* 0 0 2.9E-6 N/A
32 Bax* m 0 0 2.9E-6 N/A
33 Bcl-2 30000 0.00870 2.9E-6 0.294
34 Bax* m:Bcl-2 0 0 2.9E-6 N/A
35 Bax*2_m 0 0 2.9E-6 N/A
36 Bax*2_m:Bcl-2 0 0 2.9E-6 N/A
37 Bax*4_m 0 0 2.9E-6 N/A
38 Bax*4_m:Bcl-2 0 0 2.9E-6 N/A
39 Pore 500000 0.21750 2.9E-6 0.25
40 Bax*4:Pore 0 0 2.9E-6 N/A
41 Pore* 0 0 0.0001 N/A
42 CytoC_m 500000 0.21750 2.9E-6 0.25
43 M*:CytoC_m 0 0 2.9E-6 N/A
44 CytoC_r 0 0 2.9E-6 N/A
45 Smac 100000 0.04350 2.9E-6 0.25
46 M*:Smac 0 0 2.9E-6 N/A
47 Smac_r 0 0 2.9E-6 N/A
48 CytoC 0 0 2.9E-6 N/A
49 Apaf 100000 0.04350 2.9E-6 0.25
50 Apaf:CytoC 0 0 2.9E-6 N/A
51 Apaf* 0 0 2.9E-6 N/A
52 Caspase-9 100000 0.04350 2.9E-6 0.25
53 Apoptosome 0 0 2.9E-6 N/A
54 Apoptosome:Caspase-3 0 0 2.9E-6 N/A
55 Smac 0 0 2.9E-6 N/A
56 Apoptosome:XIAP 0 0 2.9E-6 N/A
57 Smac:XIAP 0 0 2.9E-6 N/A
58 Caspase-3*_Ub 0 0 2.9E-6 N/A
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Table 2: Kinetic rate parameters.
See (Albeck, Burke et al. 2008b) for reaction equations. * indicates units of 1/s.
forward
rates
kl
k2
k3
k4
k5
k6
k7
k8
k9
k10
kll
k12
k13
k14
k15
k16
k17
k18
k19
k20
k21
k22
k23
k24
k25
k26
k27
k28
k29
k30
k31
reverse1/(s*molec/cell)
4.00E-07*
1.00E-06
1.00E-07
1.00E-06
1.00E-07
1.00E-07
1.00E-07
2.00E-06
1.00E-06
1.00E-07
1.00E-06
1.00E-07
0.01
1.00E-06
1.00E-06
1.00E-06
1.00E-06
1.00E-06
1.00E-06
2.00E-06
2.00E-06
1
5.00E-07
5.00E-08
5.00E-09
1
2.00E-06
7.00E-06
5.00E-08
6.00E-07
0.01
1/s catalytic
rates
krl
kr2
kr3
kr4
kr5
kr6
kr7
kr8
kr9
krl 0
krl 1
krl 2
kr13
kr14
krl 5
kr16
krl17
krl18
krl 9
kr20
kr21
kr22
kr23
kr24
kr25
kr26
kr27
kr28
kr29
kr30
kr31
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kcl
kc2
kc3
kc4
kc5
kc6
kc7
kc8
kc9
kcl 0
kcl 1
kcl 2
kcl 3
kc14
kc15
kc16
kc17
kcl 8
kcl 9
kc20
kc21
kc22
kc23
kc24
kc25
kc26
kc27
kc28
kc29
kc30
kc31
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1.00E-06
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
1
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.01
0.001
0.001
0.001
0.01
0.001
0.001
0.001
0.001
0
1E-02
0
1
0
1
1
1
0.1
20
1
0
1
0
0
0
0
0
0
1
10
10
0
1
0
1
0
0
0
1
0
0
Chapter 3
3 Simulating a population of TRAIL-treated cells with
a population of models
This chapter is based upon:
Computational analysis of variability in TRAIL-induced apoptosis
(In preparation)
Suzanne Gaudet*, Sabrina L. Spencer*, William W. Chen, and Peter K. Sorger
(* These authors contributed equally to this work.)
In TNF-related apoptosis inducing ligand (TRAIL)-mediated apoptosis, cells enter a long
and variable delay period prior to sudden activation of effector caspases that rapidly kills the cell.
We have previously shown that variability in death time largely results from cell-to-cell
variability in the levels or activity states of protein regulators of apoptosis. Here we establish a
method for modeling variability in cellular output caused by cell-to-cell variability in initial
conditions. We also develop novel, intuitive forms of sensitivity analysis which can be directly
tested experimentally. Modeling predicts, and experiments confirm, that a cell's response to
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increasing Bcl-2 levels can be described as a step function where cells resist death entirely above
a threshold level of the protein. We perform the simulations with and without measured
covariance in initial conditions, revealing a moderate impact on variance in death time but a
large impact on sensitivities. These differences underscore the need to consider cellular
contexts, such as covariance in two antagonistic protein species, when building biological
models.
3.1 Introduction
Mathematical modeling of complex signal transduction pathways is essential for
understanding the highly non-linear and therefore non-intuitive behavior of signal propagation.
Most models of induced signal transduction in mammalian cells use deterministic equations to
mimic the average behavior of a population of cells (Hoffmann, Levchenko et al. 2002; Bentele,
Lavrik et al. 2004; Hua, Cornejo et al. 2005; Legewie, Bluthgen et al. 2006; Chen, Schoeberl et
al. 2009) or explicitly model a single representative cell from a population (Eissing, Conzelmann
et al. 2004; Altan-Bonnet and Germain 2005; Geva-Zatorsky, Rosenfeld et al. 2006; Albeck,
Burke et al. 2008b). With the exception of several studies that use stochastic simulations
(Eissing, Allgower et al. 2005; Geva-Zatorsky, Rosenfeld et al. 2006; Toettcher, Loewer et al.
2009), variability from cell-to-cell has been largely ignored in modeling or treated as merely the
standard deviation of an aggregate measurement. However, much can be learned from treating
cell-to-cell variability not as noise or error, but rather as remarkable differences from cell-to-cell
that can be modeled deterministically and can have an impact on cell fate.
Several recent papers have highlighted the consequences of variability in protein levels
for biological processes ranging from differentiation (Chambers, Silva et al. 2007; Chang,
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Hemberg et al. 2008) to drug-induced cell death (Cohen, Geva-Zatorsky et al. 2008), including a
recent report from our group on TRAIL-mediated apoptosis (Spencer, Gaudet et al. 2009). The
TRAIL signaling network represents an unusual variable delay, snap-action switch that forces an
unequivocal and irreversible life-or-death decision (Albeck, Burke et al. 2008b). During the
variable delay period, upstream initiator caspases are active, but mitochondrial outer membrane
permeabilization (MOMP) has not occurred and downstream effector caspases are inactive
(Albeck, Burke et al. 2008b). In many cell types, the decision period becomes a commitment to
certain death once the MOMP threshold is crossed. This causes the release of pro-apoptotic
proteins from the mitochondrial outer membrane; these proteins converge to rapidly activate
effector caspases that destroy the cell.
The signaling pathway (Fig. 3.1a) that creates such a variable delay, all-or-none switch
can be triggered by the binding of one of the TNF (tumor necrosis factor) family of ligands,
which include TNFa, Fas ligand, and TRAIL. TRAIL ligand stimulation induces the
trimerization of its receptors on the cell surface, DR4 and DR5. This initiates assembly of the
death-inducing signaling complex (DISC), which activates initiator caspases-8 and -10 (hereafter
C8). Activated C8 can directly cleave effector caspases-3 and -7 (hereafter C3), however
complete activation of C3 requires activation of the mitochondrial pathway in most cells (the so-
called 'Type II' cells). This step occurs because C8 also activates and cleaves Bid to tBid, which
in turn activates Bax via conformational change. Active Bax translocates to the mitochondria,
where it causes mitochondrial outer membrane permeabilization (MOMP) by the formation of
pores in the outer membrane of the mitochondria. The pro-apoptotic activity of active Bax and
tBid is antagonized, however, by the anti-apoptotic Bcl-2 family of proteins, which act as a
buffer for active Bax and tBid. Upon permeabilization, the mitochondria release in an all-or-
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none fashion a potent mixture of pro-apoptotic proteins, including cytochrome c and Smac.
Cytochrome c forms the apoptosome complex with Apaf-1 and caspase-9 (C9), which activates
additional C3. This activation is aided by Smac's inhibition of XIAP, which inhibits active C3.
A positive feedback loop mediated by caspase-6 (C6) serves to amplify the death signal under
certain conditions. C3 goes on to kill the cell by activating DNases that fragment the genome,
cleaving DNA repair enzymes such as PARP, and cleaving structural proteins such as
cytokeratins and nuclear lamins.
There are several features that describe the trajectory a cell can take from TRAIL
stimulation to death (Fig. 3.1b). The 'decision' phase of the pathway lies upstream of MOMP
and can be described as a variable rate of approach to a threshold of variable height (Spencer,
Gaudet et al. 2009). The rate of approach (kic), the height of the MOMP threshold (0), and the
timing of MOMP (tMOMP) can be measured in single cells using live-cell fluorescent reporters of
initiator caspase activation (IC-RP) and MOMP (IMS-RP) (Albeck, Burke et al. 2008a, Spencer,
Gaudet et al. 2009). After MOMP occurs, the cell is committed to apoptosis by means of
effector caspase activation, which can be monitored using fluorescent reporter EC-RP (Albeck,
Burke et al. 2008a). The time between exposure to TRAIL and the time of half-maximal
cleavage of effector caspase substrates such as PARP is termed tPARP. The cleavage of effector
caspase substrates rapidly rises to a plateau, at which point the cell has died; the fraction of
effector caspase substrate cleavage at this plateau is termedf. The switching time between initial
and complete effector substrate cleaveage is termed ts. Together, these six features describe a
cell's path through the pre-MOMP decision phase (kIc, 0, tMOMP) through to the death of the cell
(tPARP, f ts).
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Here we develop a modeling methodology that accounts for the observed cell-to-cell
variability in TRAIL signaling by modeling a population of cells using a population of
deterministic models with distributions of initial conditions informed by our experimental
measurements. Using this framework, we address the relative importance of proteins in the
apoptosis network with novel types of sensitivity analysis that can be directly compared to
single-cell experiments. The network is revealed as a complex landscape where various species
can appear significant depending where its initial condition resides, underscoring the importance
of knowledge of protein level mean and variance for meaningful sensitivity analysis. We find
that the determination of death time is multifactorial, and that even perfect knowledge of the
concentration of the most sensitive model species only returns partial predictability of a cell's
death time in a background where all proteins' initial conditions are variable.
3.2 Results
3.2.1 Modeling a population of cells with a population of models
We have previously shown that variability in death time is in large part due to variability
in protein levels. We therefore measured the spread in steady state levels of several apoptosis
regulators in a clonal population of HeLa cells using immuno-fluorescence and flow cytometry
(Fig. 3.1c-e). The antibodies used to measure total protein were validated by siRNA and
overexpression (Supplementary Fig. 3.1 and 3.2). To ensure that antibody binding was not
adding a substantial amount of variation to our total protein measurements, we assessed how
well a signal from antibody binding matched a known amount of cellular GFP fluorescence (Fig.
3.1 d). Variation extending along the diagonal represents real cell-to-cell differences in the level
of protein, whereas off-diagonal variation reflects disagreement between the protein abundance
measured by antibody and the known abundance as read out by GFP fluorescence. We found
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that off-diagonal variation was much smaller than true cell-to-cell variation and could be safely
ignored. All protein distributions measured were found to fit a log-normal distribution
(Supplementary Fig. 3.3), with a coefficient of variation (CV, standard deviation/mean) of about
0.44 (Fig. 3.1c). Subsequently, we gated on a subset of cells with similar forward scatter and
side scatter values in order to select a subpopulation of cells of similar size, and found that the
CV of the protein distributions decreases to about 0.29, in accordance with similar measures of a
different set of proteins made by live-cell microscopy (Sigal, Milo et al. 2006). The un-gated
data measure dispersion in total protein amount, while the size-selected data measure dispersion
in protein concentration. We also compared these measurements to ones made by immuno-
fluorescence microscopy (where cell size was assessed by nuclear area) and found good
agreement (data not shown).
Using a previously developed differential equation model of TRAIL-induced apoptosis
describing a typical HeLa cell's response to TRAIL (Albeck, Burke et al. 2008b), we modeled a
population of similarly sized HeLa cells with a population of models where cells vary in their
initial proteins levels. We used the measured CV for the five proteins measured in Fig. 3.1 c, or
assumed a log-normal distribution with a CV of 0.25 for the 12 remaining initial conditions. To
model a population of cells, we ran numerous deterministic simulations of this model, each time
randomly and independently sampling from the log-normal protein distributions to pick the
number of copies of each protein in that simulated cell. By plotting the distribution of tPARP as a
model output for a population of these simulated cells, we found that the variability in the
model's initial conditions propagates through the pathway to recapitulate the experimentally
observed variability in death time over a wide range of doses (Fig. 3.1h and ref. Spencer, Gaudet
et al. 2009).
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Figure 3.1. Measurements of variability in protein levels in the TRAIL-induced apoptosis network. a, The TRAIL-induced
apoptosis pathway as described in the text. Fluorescent protein reporters IC-RP, EC-RP, and IMS-RP are indicated. b,
Idealized IC-RP (top) and EC-RP (bottom) trajectories indicating the six features discussed in the text. c, Selection of cells
of similar size by gating on side scatter (SSC) and forward scatter (FSC); white box marks the selected cells. d, Distribution
of protein levels in a population of cells as measured by immunostaining and flow cytometry. e, Comparison of the coeffi-
cient of variation (CV) for the distributions of protein levels in (d). Error is the standard error of the mean from independent
measurements. f, HeLa cells stably expressing GFP-Bcl-2 (x-axis) were stained with anti-BcI-2 (SC7382) followed by a
secondary antibody conjugated to Alexa Fluor 647 (y-axis). An increase in known Bcl-2 abundance (observable by the GFP
tag) is matched by an increase in the measured amount of Bcd-2 using the antibody, g, Off-diagonal variation (mismatch in
known BcI-2 relative to measured Bci-2 abundance) is small compared with diagonal variation (true variation in the amount
of Bd-2 from cell to cell). IQR, interquartile range. h, Distribution of tp, in populations of simulated cells for five doses of
TRAIL. Each cell's initial protein levels were sampled independently from log-normal distributions.
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3.2.2 Forward propagation of variability in initial conditions to timing of death
Given that all five proteins measured were found to be similarly log-normally
distributed with CVs of about 0.29, we questioned whether variability in all proteins contributed
equally to producing variability in tPARP or whether variability in certain proteins was more
influential than others. To determine which components of the apoptotic pathway provide the
majority of the heterogeneity in t PARP, we performed a computational scan of the effect of
variability in single proteins on tPARP. This involved running a set of simulations for each of the
17 initial conditions, with sampling from a log-normal distribution for the protein in question
while all other proteins were held constant at their default level. We then compared the variance
in tPARP from the first set of simulations where all initial conditions are allowed to vary
simultaneously, to these simulations where only one protein is varied at a time (Fig 3.2). We
find that variability in several proteins at the top of the pathway controlling rate kc (namely
Receptor, C8, and Bid) as well as the two main proteins controlling the MOMP threshold 0
(namely Bax and Bcl-2) can each significantly contribute to variability in tPARP. In contrast,
proteins downstream of MOMP contribute little to variability in tPARP. These findings are
consistent with experiments showing that the majority of the variability in time-to-death lies
upstream of MOMP (Spencer, Gaudet et al. 2009). We noted that the sum of variability in the
individual network components did not equal the variability in output when all protein levels
were allowed to vary simultaneously. This is a result of high nonlinearity in the model and the
fact that the combined effect of individual contributions likely involves an operation more
complex than simple addition.
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Figure 3.2. Propagation of variability in initial conditions to produce variability in tp,,. a, Synthetic distributions of 16 of 17
initial protein species; omitted is the distribution from cell to cell in the number of possible pores in the mitochondrial outer
membrane. Distributions are log-normal with CVs as measured (Fig. 2.1e), or set to 0.25 if unmeasured. b, Distribution of
death times (measured by t.) when the variation in one protein species at a time simulated, with all oth er species held
constant at the mean value. c, Data from (a) plotted as a bar graph. d, Results from (b) plotted as a bar graph; the CV for
simulations from Fig. 2.1h with all initial conditions varying simultaneously is included for comparison ("All"). Simulations
were run with 50 ng/ml TRAJL.
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3.2.3 Correlations in initial conditions reduce variance in death time
The simulations in Fig. 3.1h allowed all initial conditions to vary in an uncorrelated
fashion. We next considered the effect of correlations in the levels of initial conditions. Using
two color flow cytometry, we measured the degree of correlation in ten pairs of initial conditions
using cells of similar size as described above. We found a range of linear correlation coefficients
(R2) ranging from an average of 0.15 for C3 and Bcl-2 to 0.53 for Bax and Bcl-2 (Fig. 3.4a,b). A
positive control using two different Bcl-2 antibodies always produced the highest correlation
among the pairs (R2=0.62 - this correlation is less than one because the two antibodies have
overlapping epitopes). This range of correlations is consistent with measures of different pairs of
proteins made by microscopy (Sigal, Milo et al. 2006). We did not detect anti-correlation
between any pairs of proteins. This could result from the fact that positive correlation in gene
expression could be more easily achieved by a cell (via use of the same transcription factor, the
same miRNA targeting mRNAs, or the same regulation of degradation) and thus more common
than active negative correlation. In addition, some variability in cell size could be present even
after our size selection process and could inflate positive correlations.
We next used the ten measured pair-wise correlations from Fig. 3.3b as inputs for a new
set of simulations; proteins whose correlations were not measured were left uncorrelated (see
Methods). We found that including knowledge of correlations in initial conditions reduced the
variability in tPARP by 18%, from a CV of 0.23 to a CV of 0.19 for 50 ng/ml TRAIL (Fig. 3.3c),
providing a better match to experimental data (Fig. 3.3d). A similar reduction in CV was seen at
all doses of TRAIL (Fig. 3.3d).
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Figure 3.3. Correlations in protein levels affect the distribution of death times. a, Correlation between the levels of
pairs of proteins in a population of cells measured by immunostaining and flow cytometry for the least correlated pair
(left) and the most correlated pair (right) measured. The R2 was calculated by linear regression. b, Measured
correlation in the levels of ten protein pairs plus a positive control of Bcl-2 against itself using two different Bcl-2
antibodies. c, Comparison of the distribution of " with independent sampling of initial conditions (blue) or with the
ten pair-wise correlations as measured in (b) and independent sampling of all other proteins. d, CV of death time for
the two types of simulations in (c) as measured by tP, or as measured experimentally by monitoring IMS-RP
transocation using live cell microscopy.
3.2.4 A biologically driven sensitivity analysis
Thus far, we have addressed responses to measured endogenous variability in protein
levels. However, additional features may be revealed by probing sensitivity outside the range of
endogenous variation, as is commonly done by experimental knock-down and overexpression.
For one protein at a time, we simulated a knock-down and an overexpression of each of the
model species, allowing the initial conditions to vary in a uniform fashion from 102-107 proteins
per cell and observing the effect on death time (Fig. 3.5a). In a first set of simulations, we
predict the average cell behavior by holding all other 16 proteins constant at their mean value.
Pro-apoptotic proteins upstream of the MOMP (Receptor, C8, Bid, Bax) have a negative slope
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while anti-apoptotic proteins (FLIP, Bar, Mcl-2, Bcl-2) have a positive slope. Varying the levels
of proteins downstream of the mitochondria has little effect on tMOMP. Of note are the complex,
nonlinear, and asymmetric sensitivities observed when a protein's level is increased or
decreased, making intuition based on pictorial pathway representations unreliable. In general,
pro-apoptotic proteins are more sensitive to having their levels decreased and anti-apoptotic
proteins more sensitive to having their levels increased. By observing where a population's
range of endogenous protein expression levels falls, we are able to understand why certain cells
are very sensitive to some proteins' initial concentrations and not to others. For example,
simulation predicts that HeLa cells sit very close to a threshold level of Bcl-2 above which the
death time increases rapidly, to the extent that cells might actually survive the death stimulus.
As these simulations can be directly compared with live-cell microscopy of TRAIL-treated cells
overexpressing fluorescently tagged proteins, this type of simulation is a biologically testable
form of sensitivity analysis.
To test this prediction, we forced a spread in the levels of Bcl-2 or its homolog Bcl-xL by
ectopic expression of GFP fusions. Live-cell microscopy yielded data on the levels of GFP in
individual cells and quantitative immunoblotting yielded a population average for the number of
molecules per cell (Supplementary Fig. 3.4 and 3.5); we combined this information to convert
the x-axes of Fig. 3.4c,d into units of proteins/cell. We treated these cells with TRAIL and the
protein synthesis inhibitor cycloheximide and scored the time of MOMP (tMOMp) in each cell by
monitoring IMS-RP translocation (Albeck, Burke et al. 2008a). When treated with TRAIL plus
cycloheximide, 100% of wild-type HeLa cells die by apoptosis. However, when tMOMP was
plotted relative to the initial level of GFP-Bcl-2 or GFP- Bcl-xL in individual HeLa cells
overexpressing these proteins, we discovered a sharp threshold in the fate of these cells as
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predicted by simulation (Fig 3.4b,c). At low fusion protein levels, MOMP occurred -2-5 hr after
TRAIL addition, while at high fusion protein levels, MOMP was blocked indefinitely. At
intermediate levels (shaded yellow in Fig. 3.4b,c), cell fate was variable with a subset of cells
undergoing MOMP and the others not. We presumed that cell-to-cell variability in the levels of
other apoptotic proteins determines outcome in the variable region, whereas at very high levels
of Bcl-2 and Bcl-xL (protein levels above the yellow shading in Fig. 3.4b,c), pro-apoptotic factors
never reach a concentration high enough to induce MOMP.
To study this region of variable fate more closely, we ran a second set of simulations.
Here, we used correlated sampling as in Fig. 3.3c, and added a uniformly distributed
overexpressed amount of Bcl-2 ranging from endogenous levels to 106 proteins/cell to match the
experimental data. This additional realism allows us to reproduce the region of variable fate in
simulation and provides a reasonable match between model and experiment (Fig. 3.4d). We can
now ask why, for a fixed amount of GFP-Bcl-2, one cell lives while another dies. We found that
variability in the levels of other proteins controlled the fate of the cell, but there was no single
protein that was primarily responsible for the bifurcation in fate (Fig. 3.4e,f). Close to a sharp
threshold, small changes can have a large impact. This appears to be such a case - small
differences in the levels of many other proteins combine to change the cell's fate.
Another noteworthy feature of these overexpression experiments is the observation that
increasing Bcl-2 and Bcl-xL levels cause only a very minor increase in tMOMP for levels below the
region of variable fate (Fig. 3.4b,c and Supplementary Fig 3.6). Consistent with these two
proteins contributing to 0 (the threshold height), they have less impact on the timing of death
compared to proteins involved in kic. A small increase in 0 can slightly delay MOMP (Spencer,
Gaudet et al. 2009), but the effect of a large increase in 0 is to prevent a cell from crossing the
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threshold for MOMP entirely. Thus, kic primarily affects the timing of death, while 0 primarily
affects whether a cell lives or dies (with a minor effect on timing).
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Figure 3.4. Effect of knock-down and overexpression of protein levels on ,.~ a, The 16 initial conditions from Fig.
3.2a were varied one at a time over five orders of magnitude and the effect on t" plotted; all other proteins were
held constant at the default value. Double grey bars indicate the 5th and 95th percentiles of the endogenous distribu
tion. b, Experimental analysis of the effect on t of overexpressing GFP-Bcd-2 in HeLa cells on a cell-by-cell basis.
MOMP was scored using IMS-RP. Cells remaining alive at the end of the 16 hr movie are indicated at >16 hr. Yellow
shading indicates the region of variable fate. c, Same as (b) but for the Bcl-2 homolog Bd-x. d, Effect on t of
increasing Bcl-2 levels in simulation on a background of variability to reproduce the region of variable fate. Simula-
tions were run with correlated sampling from log-normal distributions as in Fig. 3.3 but with an additional uniform
amount of overexpressed Bdc-2. Two cells with similar levels of overexpressed Bcl-2 but with different fates are
indicated in orange and blue and are described in (e) and (f) . e, Initial conditions of the orange cell indicated in (d)
with 59,714 GFP-Bd-2 proteins per cell and tmow = 4.6 hr. f, Initial conditions of the blue cell indicated in (d) with
52,838 GFP-Bcl-2 proteins per cell and no MOMP by the end of the 12 hr simulation. Initial protein levels in the two
cells have been normalized to the average (default level) of that species.
A third aspect of these overexpression data is that -360,000 GFP-Bcl-2 proteins/cell (-13
fold over endogenous Bcl-2) versus -900,000 GFP-Bcl-xL proteins/cell (-120 fold over
endogenous Bcl-xL) are required to prevent MOMP (Fig. 3.4b,c). However, we note that the
number of copies needed to reach a point where all of the cells survive is not necessarily a
function of the fold overexpression over endogenous, but rather a function of the absolute
number of copies sufficient to overwhelm variability in all other determinants of cell fate. The
difference in the total number of Bcl-2 proteins (-360,000 + -30,000 endogenous) or Bcl-xL
proteins (-900,000 + -8,000 endogenous) needed to prevent MOMP leads us to predict that in
HeLa cells, Bcl-2 is a more potent inhibitor of death than Bcl-xL. This could be due to the
number of pro-apoptotic partners that Bcl-2 is able to buffer and/or its relative affinity for these
targets. The relative affinities of Bcl-2 and Bcl-xL for a protein like Bax are as yet impossible to
measure in vivo (for Bax in its activated conformation), but we are potentially observing their
effects in these experiments.
3.2.5 Reverse prediction of death time given incomplete knowledge of initial conditions
Given the importance of Bid, Bax, and Bcl-2 in the forward simulations, and the
availability of validated antibodies to these three proteins, we asked whether knowledge of the
levels one or two of these proteins would be sufficient to distinguish experimentally between
cells that would die quickly after treatment with TRAIL and cells that would take longer to die.
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Using simulations with correlated initial conditions as in Fig. 3.3c, we compared the levels of
Bid, Bax, and Bcl-2 in 'untreated' cells (the full population of initial conditions) with cells that
were still alive after 2.5 hr of treatment with TRAIL plus cycloheximide. We saw only a slight
reduction of cells with high Bid and Bax levels in the population of cells that remained alive
after 2.5 hr of treatment (Fig 3.5a). Based on these results, we predicted that these differences
would be too small to measure in a corresponding flow cytometry experiment, which we found
to be the case (Fig. 3.5b). Furthermore, simultaneous knowledge of the levels of two proteins in
a single cell also failed to distinguish untreated cells from cells that remained alive after 2.5 hr of
treatment. In the experiments, one could attribute this negative finding to error in the
experimental methods that prevent such subtle differences from being measurable
(Supplementary Fig. 3.8). However, even in our deterministic simulations where we know that
variability in Bid, Bax, and Bcl-2 propagates forward through the pathway to produce variability
in death time, we are unable to detect in reverse the differences in protein levels that cause the
variability in death time.
A more time-consuming but nevertheless feasible experimental approach would be to
endogenously label proteins corresponding to sensitive model species with a fluorescent tag and
then to ask whether knowledge of a protein's level is predictive of a cell's death time. As was
demonstrated for four proteins contributing to kc in simulations with independently sampled
initial conditions (Spencer, Gaudet et al. 2009), and shown here for all proteins in the model with
correlated initial conditions (as in Fig. 3.3c), the answer was no (Fig. 3.6a). Variability in other
proteins obscured the contribution from any individual protein. However, the extent to which the
rank ordering of sensitivities changes when the simulations are run with and without correlated
initial conditions is noteworthy (Fig. 3.6b). The sensitivity of Bcl-2 changes the most
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dramatically - Bcl-2 is the second most sensitive protein when the simulations are performed
with independent sampling, but is second to last in sensitivity when initial conditions are
sampled using the measured covariance. Thus, although knowledge of correlations in initial
conditions had only a moderate impact on the CV of tpARP, it has a large impact on the rank
ordering of sensitivities.
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Figure 3.5. The levels of single or double proteins are not detectably different in untreated cells andTRAIL survivors, a, Levels of Bid, Bax, and Bcl-2 in untreated cells (the total population, red) versus cells
remaining alive after 2.5 hr of treatment with 50 ng/ml TRAIL ("survivors", blue) using simulations run with
correlated initial conditions as in Fig. 3.3c. b, Same as (a) but via experimental analysis of immunostained
cells and flow cytometry (see also Supplementary Fig. 3.8). c, Same as (a), but now examining whether
the levels of a pair of proteins is significantly different in untreated cells versus "survivors" using simulation.d, Same as (c) but via experimental analysis of immunostained cells and flow cytometry.
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3.3 Discussion
In this work, we develop methods for modeling variability in cell behavior that results
from variability in initial conditions. The idea that variability in cellular response can be
modeled by variability in protein levels has been suggested previously (Eissing, Conzelmann et
al. 2004; Wilkinson 2009), but we are the first to implement such a modeling effort. The
primary source of heterogeneity in the timing of apoptosis induced by TRAIL in the presence of
cycloheximide was recently shown to be a result of cell-to-cell variability in protein levels that
exists prior to treatment (Spencer, Gaudet et al. 2009). As pairs of sister cells had very similar
death times, stochasticity in the TRAIL-induced protein signaling cascade, as is typically
simulated using the Gillespie algorithm, plays a minimal role. We therefore are able to use a
deterministic framework with random sampling from measured distributions of protein levels to
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simulate a population of cells. We develop three novel forms of sensitivity analysis in Fig. 3.2,
3.4, and 3.6 that should be much more intuitive for biologists than a classical sensitivity analysis.
Moreover, two of these analyses (Fig. 3.4 and 3.6) are analogs of experiments that can be
performed using live-cell microscopy.
Our primary biological discovery relates to the extreme nonlinearity in a cell's response
to Bcl-2 and Bcl-xL levels, a finding that was predicted by our model. The ability of Bcl-2 and
Bcl-xL to prevent apoptosis has been known for some time (Vaux, Cory et al. 1988; Hockenbery,
Nunez et al. 1990; Boise, Gonzalez-Garcia et al. 1993). However, our single-cell analysis
provides a precise mapping between a cell's Bcl-2 or Bcl-xL overexpression level and its death
time. We note that MOMP can be blocked indefinitely by a 13-fold overexpression of Bcl-2 in
HeLa cells, a fold increase reached in acute lymphoblastic leukemias (Coustan-Smith, Kitanaka
et al. 1996). Bcl-2 is a more potent inhibitor than Bcl-xL of TRAIL-induced apoptosis in HeLa
cells. The difference in Bcl-2 and Bcl-xL levels required to block MOMP may reflect differences
in the relative affinities of these proteins for their pro-apoptotic binding partners that are not
currently measurable in living cells.
We highlight two key computational findings pertaining to the creation of accurate
biological models. First, we find that while including knowledge of correlations in initial
conditions had a moderate impact on variance in death time, it had a large impact on the
sensitivities of initial conditions. Correlations can change the apparent importance of proteins,
especially when a protein's level is correlated with the level of its direct antagonist, as is the case
for Bcl-2 and Bax. A cell with high Bcl-2 may have had a delayed death time in the case of
independent sampling of initial conditions, but if high Bcl-2 results in the cell simultaneously
having high Bax, the anti-apoptotic effect of Bcl-2 will be negated. Thus, knowledge of the
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biochemistry must be supplemented by knowledge of cellular context, as co-variation in a highly
non-linear model can produce surprising results.
Second, our simulations underscore the need for accurate knowledge of the mean and
variance of key protein levels when modeling - a small error in the estimates of sensitive
species' mean levels can result in large inaccuracies in the distribution of death times or in
estimations of sensitivity. For example, we found that doubling the initial condition for Bcl-2
from our measured level of 3x10 4 Bcl-2 proteins/cell (Supplementary Fig. 3.4) to 6x10 4 had a
significant impact on the CV of tMOMP and on the relative importance of pathway proteins, to the
extent that Bax and Bcl-2 become the most dominant species (Supplementary Fig. 3.7). This
inflated sensitivity is inconsistent with experimental data showing the importance of kic in
determining time-to-death (Spencer, Gaudet et al. 2009) and highlights the need for accuracy in
assigning the initial conditions of sensitive model species.
While we have measured the absolute levels of several of the most important species
using quantitative immunoblotting (Supplementary Fig. 3.4 and 3.5 and ref. Spencer, Gaudet et
al. 2009), our manually calibrated model could reside in a local minimum. However, the mean
as well as the variance in cell responses measured in various single-cell experiments can be used
for automated parameter estimation and model calibration. Future model calibration efforts
should therefore consider cell-to-cell variability as valuable data that can constrain the
calibration of a model.
The biologically driven way of viewing species' sensitivities described in this paper
reveals why slight variations in the levels of certain proteins can have a huge impact on a cell's
death time. HeLa cells are tuned such that their initial protein levels fall in sensitive regions of
initial condition space, guaranteeing variability in response to TRAIL. Cells can evolve toward
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optimal protein expression levels (Dekel and Alon 2005), suggesting that there may be an
evolutionary advantage for cells to have a high level of tunability. During development or adult
homeostasis, variability in sensitivity to apoptosis provides a way to bring about a graded
response at a cell population or tissue level, despite a binary output at the single cell level.
However, we have thus far only modeled variability in the timing of death in cells treated with
TRAIL plus cycloheximide. A next step will be to examine cells treated with TRAIL alone to
determine whether, in the limit, variability in timing becomes variability in fate. Such modeling
awaits additional biological knowledge surrounding which survival pathways are most influential
in producing variability in cell fate.
3.4 Methods
Transfections. HeLa cells expressing IMS-RP (Albeck, Burke et al. 2008a) were stably
transfected using FuGENE 6 (Roche) with pExchange vectors (Stratagene) into which we cloned
cDNAs for EGFP-Bcl-2 or EGFP-Bcl-XL. Stable transfectants were isolated by neomycin and
sorted on a FACSAria (BD Biosciences) to sample expression levels across a wide range.
Live-cell microscopy. HeLa cells expressing IMS-RP and GFP-Bcl-2 or GFP-Bcl-xL
were plated in a 96-well glass bottom plate (Matrical). Cells were treated with 50 ng/ml TRAIL
and 2.5 ug/ml cycloheximide and imaged on a Nikon TE2000E at 20x magnification with frames
every 5 min in a 370C chamber in phenol-red free C0 2-independent medium (Invitrogen)
supplemented with 1% fetal bovine serum (Mediatech), L-Glutamine (Gibco) and Penicillin/
Streptomycin (Gibco). GFP-Bcl-2 or GFP-Bcl-xL fluorescence was quantified at t = 0 (time of
treatment) by manually outlining the cell and measuring the average fluorescence intensity
within the outline. MOMP was scored by monitoring cytosolic translocation of IMS-RP. To
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convert the x-axes in Fig. 3.4b,c to proteins/cell, the average GFP fluorescence intensity from
these movies was set equal to the average number of GFP-tagged proteins per cell as measured
by quantitative immunoblotting (Supplementary Fig. 3.4 and 3.5).
Flow cytometry. The distributions of initial protein levels were measured in untreated
HeLa cells (fixed with paraformaldehyde and permeabilized with methanol) on a FACSCalibur
in Fig. 3.1 and 3.3 or on a FACSCanto in Fig. 3.5 (BD Biosciences). The antibodies were
carefully validated as described in Supplementary Fig. 3.1 and 3.2. The following antibodies
were used to measure total protein levels: a-Bid (HPA000722, Atlas Antibodies), a-Bax
(MAB4601, Chemicon International), a-Bcl-2 (SC7382 or SC783, Santa Cruz Biotechnology),
a-XIAP (610717, BD Biosciences), a-C3 (SC7272, Santa Cruz Biotechnology). Correlations in
protein levels were measured by combining pairs of antibodies of different species or using the
primary antibodies listed above conjugated to differing fluorophores (C3-AF488, Bax-PE, XIAP-
AF647). In Fig. 3.6, "survivors" were cells negative for cleaved PARP (51-9000017, BD
Biosciences) or cleaved C3 (559565, BD Biosciences) at 2.5 hr of treatment.
Modeling. The first most basic set of simulations in Fig. 3.1h was performed as in
(Spencer, Gaudet et al. 2009) using the EARMv1.1 ordinary differential equation model (Albeck,
Burke et al. 2008b). This model was manually calibrated to represent the response of a single
HeLa cell to TRAIL treatment. To model a population of HeLa cells, we ran a series of 104
simulations of the model (modified to include general protein synthesis and degradation) in
Jacobian (Numerica Technology). For each run of the model (representing one cell), all 17
initial conditions were independently sampled from log-normal distributions having mean values
as in Supplementary Table 1 and coefficient of variation as measured by flow cytometry (Fig.
3.1) or set to 0.25 for proteins that were not measured. The second set of simulations in Fig. 3.2
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was performed by sampling from only one protein distribution at a time while holding all others
constant at their default mean value and assessing the impact on tPARP. The third set of
simulations (Fig. 3.3c,d, brown) was performed similarly to the first set, but included the
measured pair-wise correlations in the ten pairs of initial conditions from Fig. 3.3a,b. This was
done by creating synthetic sets of initial conditions with correlations according to the measured
R values. All other initial conditions were assumed to be independent. The fourth set of
simulations (Fig. 3.4a) involved uniformly sampling one initial condition from 102 to 107
proteins per cell, holding all others constant at the default value (no variability was simulated
here). In Fig. 3.4d, GFP-Bcl-2 (an experimental observable) was added to the level of
endogenous Bcl-2 (experimentally unobservable), which followed a lognormal distribution;
simulations were performed with correlated initial conditions as in Fig. 3.3c (brown). The
simulated GFP-Bcl-2 levels were selected to match experimental GFP-Bcl-2 levels in Fig. 3.4b.
Simulations in Fig. 3.5 and 3.6 were performed as described above for Fig. 3.3c (brown). All
experiments and simulations were performed in the presence of 2.5 gg/ml cycloheximide or the
modeled equivalent (80% reduction in protein synthesis rates).
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3.5 Supplementary figures
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Supplementary Figure 3.1. Validation
of antibodies used for measuring protein
distributions by flow cytometry. a and b,
The rabbit anti-Bid antibody (Atlas
Antibodies HPA000722) was validated
using two methods. a, HeLa cells were
treated with an siRNA for Bid or with a
non-targeting (NT) siRNA and stained
with anti-Bid followed by a secondary
antibody or with seconary antibody
alone. b, HeLa cells were transiently
transfected with Bid-GFP and stained
with anti-Bid followed by a secondary
antibody conjugated to Alexa Fluor 647
(AF647), or stained with AF647-
conjugated secondary antibody only. c
and d, The mouse anti-Bax antibody
(Chemicon International MAB4601) was
validated using two methods. c, Paren-
tal HCT116 cells that express Bax and
HCT116 Bax-/- derivatives were stained
with anti-Bax followed by a secondary
antibody or with secondary antibody
alone. d, HeLa cells were transiently
transfected with YFP-Bax and stained
with anti-Bax followed by a secondary
antibody conjugated to AF647. e, The
mouse anti-XIAP antibody (BD Biosci-
ences 610717) was validated by one
method. Parental HCT116 cells that
express XIAP and HCT116 XIAP-/-
derivatives were stained with anti-XIAP
followed by a seconary antibody or with
secondary antibody alone, f, The
mouse anti-C3 antibody (Santa Cruz
Biotechnology SC7272) was validated by
one method. HeLa cells were transiently
transfected with C3-GFP and stained
with anti-C3 followed by a secondary
antibody conjugated to AF647. g, The
mouse anti-Bcl-2 antibody (Santa Cruz
Biotechnology SC7382) was validated by
one method. HeLa cells stably express-
ing GFP-Bcl-2 were stained with anti-
Bcl-2 followed by a secondary antibody
conjugated to AF647 or stained with
AF647-conjugated secondary antibody
alone. h, The rabbit anti-Bcl-2 antibody
(Santa Cruz Biotechnology SC783) was
validated by one method. HeLa cells
were transiently transfected with GFP-
Bcl-2 and stained with anti-Bcl-2
followed by a secondary antibody
conjugated to AF647 or stained with
AF647-conjugated secondary antibody
alone.
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Supplementary Figure 3.2. Comparison of antibodies to the five proteins described in Methods with their relevant
isotype controls. a, Mean signal as a function of increasing concentrations of antibody and isotype control. For Bid, the
matched isotype control used was rabbit igG; for XIAP, Bax, and Bcl2, mouse IgG,; for C3, mouse IgG,. All isotype
controls were purchased from Santa Cruz Biotechnology. b, Fold increase in signal from antibody staining versus
background isotype control staining. Arrows indicate the concentrations of antibodies used in future experiments
whose distributions are plotted in (c). c, Assessment of the degree of overlap of distributions of isotype control- and
antibody-stained cells. Cells were fixed and permeabilized as in Methods and run on a FACSCalibur (BD Biosciences).
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Supplementary Figure 3.3.
Test of protein level distribu-
tions for log-normality. Cells
were prepared as described in
Methods and run on a FACS-
Calibur. The data were read
into MATLAB in linear form,
gated to select cells of similar
size as described in Methods,
and tested for normality using
the Kolmogorov-Smirnov test.
All distributions were found to
pass the test for normality.
This is equivalent to perform-
ing a test for log-normality
using the log transformed data
commonly plotted by the
software FlowJo. a, Distribu-
tion of data (blue) compared
with a normal fit (red). b,
Cumulative distribution
functions (CDF) of data (blue)
and normal fit (red). This
analysis was performed
together with Thomas
Norman.
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Supplementary Figure 3.4. Quantitative immunoblots for endogenous Bcl-2 and GFP-Bcl-2 in HeLa cells. Pure
protein and HeLa cell lysate were loaded on a 10% Trcine SDS-PAGE gel. After transfer to a PVDF membrane,
blots were probed, scanned on a LI-COR Odyssey scanner, and quantified digitally. a, The membrane was probed
with rabbit anti-Bd-2 (Santa Cruz Biotechnology SC783) followed by AF680-conjugated anti-rabbit. The pure Bcl-2
is a 46kD fusion protein (Santa Cruz Biotechnology SC4096). b, From the standard curve, we calculate that a single
HeLa cell has 1.57x10"1 g Bcl-2. Using 26,135 as the molecular weight of Bcl-2, we find 36,000 Bd-2/cell. The
average of 14 such measurements yields 30,000 Bcd-2/HeLa cell; s.e.m = 10,000. c, The membrane was probed
with mouse anti-GFP (Roche #11814460001) followed by IRDye 800-conjugated anti-mouse. The pure GFP was
purchased from Biovision (#4999-100). d, From the standard curve, we calculate that a single IMS-RP GFP-Bcl-2
HeLa cell has 5.68x10 15 g GFP-Bd-2. Using 27,000 as the molecular weight of GFP, we find 127,000 GFP-Bcd-
2/cell. The average of 5 such measurements yields 133,000 GFP-Bcl-2/HeLa cell s.e.m = 18,000. We set the
average (background subtracted) GFP-Bd-2 fluorescence intensity of the population of cells in the first frame of the
movie used in Figure 3.4b equal to the average number of GFP-Bcl-2 in the HeLa cells used for the movie
(calculated above) and rescaled the x-axis of Figure 3.4b into units of GFP-Bcl-2 proteins per cell.
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Supplementary Figure 3.5. Quantitative immunoblots for endogenous Bcl-x, and GFP- Bcl-x, in HeLa cells.Pure protein and HeLa cell lysate were loaded on a 10% Tricine SDS-PAGE gel. After transfer to a PVDF
membrane, blots were probed, scanned on a LI-COR Odyssey scanner, and quantified digitally. a, Themembrane was probed with rabbit anti- Bcl-xL (CST #2762) followed by AF680-conjugated anti-rabbit. Thepure Bcl-x was a gift from Emiko Fire (MIT). b, From the standard curve, we calculate that a single HeLa cellhas 2.96x10 -16 g Bcl-xL. Using 25,918 as the molecular weight of Bcl-xL, we find 6,900 Bcl-xL /cell. Theaverage of 7 such measurements yields 7,700 Bcl-x /HeLa cell; s.e.m = 1,300. c, The membrane wasprobed with mouse anti-GFP (Roche #11814460001) followed by IRDye 800-conjugated anti-mouse. Thepure GFP was purchased from Biovision (#4999-100). d, From the standard curve, we calculate that a singleIMS-RP GFP-Bcl-x HeLa cell has 1.99x10 -14 g GFP- Bcl-x L. Using 27,000 as the molecular weight of GFP,we find 445,000 GlP- Bcl-xL /cell. The average of 6 such measurements yields 579,000 GFP- Bcl-x /HeLacell; s.e.m = 200,000. We set the average (background subtracted) GFP- Bcl-x fluorescence intensity of thepopulation of cells in the first frame of the movie in used in Figure 3.4c equal to the average number of GFP-Bcl-x, in the HeLa cells used for the movie (calculated above) and rescaled the x-axis of Figure 3.4c into unitsof GFP- Bcl-xL proteins per cell.
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Supplementary Figure 3.6. Increasing BcI-2 and Bcl-x L levels cause a slight increasing
in t"
. 
Plot are reproduced from Fig. 3.4b and 3.4c and the cells undergoing MOMP fit
via linear regression (red line). t increases by 0.005 seconds for each additional
Bcd-2 or Bcl-x protein in the cell.
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Supplementary Figure 3.7. Sensitivity to doubling the level of Bcl-2. a, Distribution of death times as measured
experimentally by IMS-RP translocation for three doses of TRAIL plus cycloheximide. b, Distribution of death times as
measured in simulation with independent sampling of initial conditions and Bcl-2 levels set to the default 30,000 per cell.(a) and (b) are reproduced from Spencer et al. 2009. c, Same as (b) but with Bcl-2 levels set to 60,000 per cell. d,
Simulation results from Fig. 2.2d are reproduced. e, Simulation as in (d) except that the Bcl-2 level was set to 60,000
per cell. Bcl-2 and Bax now become the most sensitive species in the model.
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Supplementary Figure 3.8. Selection of cells that survive a 2.5 hr treatment
with 50 ng/ml TRAIL plus cycloheximide and comparison of duplicate samples.
Cells were fixed with paraformaldehyde/methano, stained, and run on a BD
FACSCalibur flow cytometer, a, Surviving cells were distinguished from dead
cells using rabbit anti-cleaved C3 (BD #559565) or mouse anti-cleaved PARP
(BD #51-9000017). Cells negative for cleaved C3 or cleaved PARP (to the left
of the dashed line) after 2.5 hr of treatement were gated and labeled "survi-
vors". b, Levels of Bcl-2 and Bid in "survivors" compared with untreated cells.
c, Measurement differences between duplicates can be as large or larger than
differences between "survivors" and untreated samples. a.u., arbitrary units.
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Chapter 4
4 Crossing the threshold for mitochondrial outer
membrane permeabilization
Section 4.1 will become part of a future manuscript involving observation of cells'
approach to the MOMP threshold as well as modulation of this threshold.
Section 4.2 is adapted from Flusberg D., Spencer S.L., Sorger P.K. "TRAIL-induced
transient resistance and heterogeneity in drug response", in preparation. The section contains
my contribution to the paper, which involved the initial observation and measurement of
transient TRAIL resistance in cells that survive an initial TRAIL challenge. These experiments
were performed together with D. Flusberg.
Section 4.3 is an excerpt from ref. Albeck, Burke et al. 2008b containing my contribution
to the paper, which involved the experimental measurements and analyses of GFP-Bax and GFP-
Bak puncta at the threshold for MOMP.
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Mitochondrial outer membrane permeabilization (MOMP) is considered the point of no
return in cell death (Keeble and Gilmore 2007). Cells that cross the MOMP threshold die rapidly
thereafter. However, even in a population of genetically identical cells treated with TRAIL,
there are cells that do not cross this threshold and survive indefinitely. Here I investigate the
differences between a cell that dies and a cell that survives, as well as what happens to these
surviving cells upon re-treatment with TRAIL. In cells that survive, I find that the rate of
cleavage of initiator caspase substrates plateaus before reaching the threshold level required to
kill the cell. These surviving cells are then transiently resistant to re-treatment with TRAIL, but
this resistance decays over the course of several days, confirming that the resistance is not
genetic in origin. Lastly, I show that formation of Bax and Bak containing pores in the
mitochondrial outer membrane is the point at which a gradual buildup of pro-apoptotic signal is
converted to a switch-like commitment to death.
4.1 Observation and modulation of the threshold for MOMP
Diverse stimuli, from oncogene activation to death receptor signals and DNA damage,
converge at the mitochondria where pro-apoptotic and anti-apoptotic signals are integrated by
members of the Bcl-2 family. Here, moderate changes in the levels of key regulators controlling
the MOMP threshold can potentially change the fate of a cell. In this section, I examine the
initiator caspase cleavage dynamics of cells that die and cells that survive TRAIL treatment, and
show that co-drugging acts to lower the MOMP threshold.
4.1.1 Monitoring the approach to the MOMP threshold in surviving and dying cells
The dynamics of initiator caspase substrate cleavage and the onset of MOMP can be
monitored in single cells treated with TRAIL using fluorescent reporter proteins IC-RP and IMS-
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RP, respectively (Albeck, Burke et al. 2008a). A population of genetically identical cells
contains a transient mixture of resistant and sensitive cells with the result that individual cells
will survive or eventually succumb to TRAIL treatment (Spencer, Gaudet et al. 2009). By
combining IC-RP and IMS-RP in single cells, a measure of the rate of accumulation of cleaved
C8 substrates and a measure of the height of the MOMP threshold can be obtained (Spencer,
Gaudet et al. 2009).
The rate of initiator caspase substrate cleavage in cells treated with TRAIL cannot easily
be fit mathematically as is possible for cells treated with TRAIL plus cycloheximide. This is at
least partly due to the ability of induced protein synthesis to change the dynamics of initiator
caspase substrate cleavage, an event not captured by our current mathematical model of TRAIL-
induced apoptosis (Albeck, Burke et al. 2008b). Nonetheless, IC-RP trajectories in HeLa cells
can be classified into three general families of cellular behaviors. First are the cells with rapid to
moderate rates of IC-RP cleavage resulting in early to intermediate MOMP times (Fig. 4.1a, first
two rows). These cells commonly show a steady rise in IC-RP signal leading to MOMP.
Second are cells whose IC-RP signal plateaus for some time before the cell undergoes
MOMP. Among single cells, the onset of the plateau phase can occur as early as 3.6 hr after
TRAIL treatment and as late as 10.5 hr, with a median time of 7 hr (Fig. 4.1 a, third row, and Fig.
4.1b). An intriguing biological explanation is that TRAIL causes the transcriptional induction of
a signal that turns off the upstream response via negative feedback, creating the plateau phase.
One potential candidate for this role is FLIP, which can be transcriptionally induced by NF-KB
and can compete for caspase-8 activation at the DISC (Micheau, Lens et al. 2001). FLIP
upregulation could be measured by immunoblot in HeLa cells. However, it is possible that FLIP
upregulation does not occur in cells that do not reach a plateau phase, and the aggregate nature of
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immunoblotting would obscure these cell-to-cell differences. A lung cancer cell line (H1299) is
available from the Kahn Dynamic Proteomics Project that contains FLIP tagged with YFP at the
endogenous locus (Spencer, Gaudet et al. 2009). FLIP levels were found to be upregulated at 8
hr in H1299 cells that survived a treatment with 50 ng/ml TRAIL; FLIP levels were constant in
untreated control cells (Fig 4.1 c). However, it is not known whether these cells show the same
plateau in initiator caspase substrate cleavage observed in HeLa cells.
There are also two alternative explanations for the plateau phase. First, it is possible that
the TRAIL present in the media degrades after several hours at 370 C, resulting in the slowing of
IC-RP cleavage. It is also possible that the plateau phase is an artifact, due to depletion of IC-
RP. Arguing against this second possibility is the sudden increase in the IC-RP signal seen in
some cells after MOMP, suggesting that the cell contains reporter that remains to be cleaved.
However, up to 40% of total IC-RP signal can be caused by the change in cell morphology
associated with apoptosis, as measured with an uncleavable initiator caspase FRET reporter
(Albeck, Burke et al. 2008a). Degradation of TRAIL could be tested with an ELISA. Possible
depletion of IC-RP could be tested by treating cells with 50 ng/ml TRAIL for -7 hours so that
many cells will have entered the plateau phase. The concentration of TRAIL could then be
increased to 250 ng/ml and cells could be monitored for an increase in the rate of IC-RP
cleavage, indicative of remaining IC-RP.
The third category of cellular behavior is survival (Fig. 4.1a, fourth row) - these are
cells that have not undergone MOMP at the end of the 23 hr observation period. A great
majority of these cells survive indefinitely, as the number of surviving cells growing the
following day is large. All surviving cells reach a plateau phase in IC-RP signal. A distribution
of the dynamics of a larger set of surviving and dying cells can be seen in Fig. 4.1 d.
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Do any features of the IC-RP trajectories differ between surviving and dying cells? One
candidate feature is the height of the threshold for MOMP. In cells that die, this threshold can be
scored as the amount of IC-RP cleaved at the time of MOMP (referred to as 0 in ref. Spencer,
Gaudet et al. 2009). In cells that do not undergo MOMP and survive, this can be scored as either
the amount of IC-RP cleaved at the end of the imaging period (Fig. 4.1 e) or as the maximum IC-
RP signal observed (data not shown). When this threshold height was compared in surviving and
dying cells, we found that threshold heights could be grouped into three levels. A "safe" region
contained only cells that survived, whereas a region of "certain death" was bounded to include
only cells that die. An intermediate region of variable fate lay in between (yellow shading),
containing dying cells with IC-RP cleavage heights that are also reached by some surviving cells.
As a side note, the fact that surviving cells reach lower IC-RP plateau values than dying cells
argues for the plateau being a result of a true negative feedback response. Put another way, if the
IC-RP plateau were merely due to depletion of the reporter, both surviving and dying cells
should reach the same plateau height.
The difference between death and survival is not binary at the level of initiator caspase
substrate cleavage. Rather, a continuum of IC-RP cleavage rates and threshold heights can be
seen among cells that die early, cells that die late, and cells that survive. Nevertheless, IC-RP
trajectories can be monitored for features that aid in distinguishing the fate of a cell. Two
features are partially informative - the height of the threshold for MOMP, and the presence or
absence of a plateau phase. It remains to be seen whether the plateau phase is an artifact due to
depletion of IC-RP, but if it represents a true feedback mechanism, the identity of the protein(s)
responsible for this feedback could be elucidated.
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Figure 4.1. The approach to the MOMP threshold in surviving and dying cells. a, Single cell IC-RP trajectories of
HeLa cells that die at various rates (gray, top three rows) and cells that survive (green, bottom row) after treatment with
50 ng/ml TRAIL. The vertical gray bar indicates the time of MOMP in each cell. A photobleaching control from
untreated cells has been subtracted from all trajectories. Trajectories are not normalized. b, Boxplot of time of plateau
onset for HeLa cells whose IC-RP trajectories plateau (dying or surviving). c, Comparison of FLIP-YFP levels in H 1299
cells left untreated (left) or treated with 50 ng/ml TRAIL (right). Fluorescence intensity was measured by manually
outlining 16-18 individual cells at 0 hr (start of imaging, and time of TRAIL treatment) or 8 hr later. In TRAIL-treated
cells, only cells remaining alive at 8 hr were considered. Mean fluorescence intensity is statisically different (by t-test) in
TRAIL-treated cells at 0 hr compared with 8 hr; means in untreated cells are not statistically different. d, Distribution of
MOMP times for cells shown in (a). "S" indicates cells that survive through the end of the movie. e, Height of the
MOMP threshold for cells shown in (a) that die (gray), as measured by IC-RP signal at the time of MOMP. For surviv-
ing cells (green), the IC-RP signal at the end of the movie is plotted. Yellow shading indicates the region of variable
fate. a.u., arbitrary units.
- 102-
10
8
CL 6
CO 4
E
I0
0
600
S500
OOas0 400
400
4.1.2 Co-drugging lowers the threshold for MOMP
TRAIL is being evaluated in clinical trials not only as a single agent, but in combination
with other targeted cancer therapies (Ashkenazi and Herbst 2008). TRAIL receptor agonists can
synergize with other drugs, as measured by aggregate methods. However, perhaps equally
important is synergy that acts to reduce heterogeneity in TRAIL response. Although not used
clinically, cycloheximide, a protein synthesis inhibitor, is one drug that has powerful synergy
with TRAIL. No matter how high the TRAIL dose, no treatment with TRAIL alone can kill all
cells in a population. However, when TRAIL is combined with 2.5 jig/ml cycloheximide (a non-
lethal cycloheximide dose over the time period considered), 100% of the cells will be killed,
even with low doses of TRAIL. Since cycloheximide can have many effects on the cell, it is not
known which are responsible for this synergy. However, live-cell imaging using IC-RP and
IMS-RP shows that the synergy is at least in part due to the fact that cycloheximide dramatically
lowers the threshold for MOMP (Fig. 4.2), bringing the threshold from an average normalized
value of 0.71 to a value of 0.46. This lowered threshold then results in a decrease in the time-to-
death because less pro-apoptotic signal is required for a cell to cross the threshold.
Synergy via lowering the threshold for MOMP has also been observed between TRAIL
and several other clinically used cancer drugs, including Gefitinib (an epidermal growth factor
receptor (EGFR) inhibitor), and Sorafenib (an inhibitor of kinases in the Raf/Mek/Erk pathway)
(D. Flusberg, unpublished observations). Future experiments on this topic will involve using IC-
RP and IMS-RP to profile the mechanisms of synergy when cells are treated with TRAIL plus a
second cancer drug. Of particular interest is Cetuximab (another EGFR inhibitor), currently in
trials as a combination therapy with TRAIL, and the promising clinical inhibitor of Bcl-2 family
proteins, ABT-737, which is thought to act by lowering the MOMP threshold.
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Figure 4.2. Cycloheximide lowers the MOMP threshold in HeLa cells treated with TRAIL. a, Normalized IC-RP trajec-
tories in cells treated with 50 ng/ml TRAIL alone. Black dot indicates time of MOMP in each cell. b, Same as (a) but for
cells co-treated with 50 ng/ml TRAIL plus 2.5 ug/ml cycloheximide. c, Comparison of height of the MOMP threshold in
cells treated with TRAIL alone or TRAIL plus cycloheximide.
4.2 Memory of TRAIL treatment in surviving cells and induced transient resistance
We have previously shown that some cells in a TRAIL-treated population live while
other cells die (Spencer, Gaudet et al. 2009). Here we show that cells which survive an initial
treatment with TRAIL are resistant to a subsequent challenge by TRAIL, but that this resistance
fades with time. Transient resistance does not appear to reflect down-regulation or adaptation of
TRAIL receptors, but rather induction of a survival response acting downstream whose effects
decay over time.
4.2.1 TRAIL treatment induces transient resistance in surviving cells
What is the difference between cells that survive TRAIL treatment and those that die?
To begin to answer this question, a clonal population of MCF 10A cells was exposed to sufficient
TRAIL (50 ng/ml TRAIL for 6 hr) to kill -80% of the cells. At this time, referred to as Day 0,
the surviving cells were then recovered by trypsinization and re-plated in fresh medium. The
recovered cells divided at approximately the same rate as untreated cells. These cells were then
exposed to TRAIL a second time one to nine days after re-plating (Fig. 4.3a) and the fraction of
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cells undergoing apoptosis was scored by flow cytometry using an antibody to the cleaved form
of PARP (cPARP; Albeck, Burke et al. 2008a). When TRAIL was added to re-plated cells at
Day 1, we observed the cells to be 5-6-fold less likely to undergo apoptosis compared to the
starting cell population: whereas -70-80% of naYve cells become cPARP positive 6 hr after
treatment with 50 ng/ml TRAIL, only -10-20% of re-plated survivors exhibited a similar
response. Insensitivity to TRAIL decreased steadily thereafter, so that by Day 6, re-plated cells
were indistinguishable from the starting cell population (Fig. 4.3b). Thus, cells that survive
initial exposure to TRAIL are resistant to a second exposure, but resistance decreases over
several days so that the initial response profile is re-established. The transient heritability of
TRAIL resistance rules out genetic mutation as a cause, and the rapidity of the return to the pre-
treatment state argues against epigenetic effects (which typically last for 10-10 5 cell generations
(Rando and Verstrepen 2007)). Instead, the data are most consistent with non-genetic effects.
a b
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Figure 4.3. Transient resistance to TRAIL-induced apoptosis in cells which survive an initial
challenge. a, Schematic of the experimental design. MCF10OA cells were treated with TRAIL for
6h. Survivors of the treatment (10-20% of the total population) were collected, re-plated, and
re-challenged with TRAIL (50ng/ml, 6h) on subsequent days in parallel with naive cells. b,
Fold-increase in surviving cells among TRAIL survivors relative to naive cells treated in parallel.
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4.2.2 Transient resistance is due to changes downstream of receptors and initiator
caspases but upstream of effector caspases.
Possible explanations for transient insensitivity to TRAIL include internalization, down-
regulation or adaptation of TRAIL receptors, phenomena that are common among other
transmembrane receptors (Ferguson and Caron 1998; Le Roy and Wrana 2005; Sorkin and Goh
2008), as well as down regulation of DISC assembly or activity. To assess these possibilities, we
monitored initiator caspase activation using flow cytometery and an antibody to the cleaved form
of caspase-3 (cC3), a direct substrate of initiator caspases. When naive MCF10A cells were
exposed to 50 ng/ml TRAIL for 6 hr, 97% stained positive for cC3 and 68% for cPARP (Fig.
4.4a). When surviving cells were recovered and re-plated (as described above), 55% retained
cC3 on Day 1, even prior to TRAIL treatment. This fraction increased to 98% following a second
exposure to 50 ng/ml TRAIL. However, only 10% of cells stained positive for cPARP,
consistent with very low levels of apoptosis (Fig. 4.4b). Thus, TRAIL-insensitive survivors on
Day 1 efficiently activate initiator caspases, even though effector caspases remain largely
inactive. We therefore conclude that the insensitivity of the surviving cells to a second TRAIL
treatment is not a consequence of receptor or DISC inactivation, but instead involves decoupling
between initiator and effector caspases: high levels of active initiator caspases are unable to
activate effector caspases. Insensitivity must therefore arise in part of the pathway that is
downstream of initiator caspases and upstream of effector caspases. This would appear to
implicate regulators of MOMP, which is blocked in the transiently resistant cells.
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Figure 4.4. Transient TRAIL resistance is not due to receptor desensitization. a and b, Initiator and
effector caspase substrate cleavage in naive cells (a) and Day 1 survivors (b) treated with TRAIL for
6h. The double-negative fraction represents live cells without initiator or effector caspase activity
(blue). The cC3-positive, cPARP-negative fraction (red) represents live cells positive for initiator
caspase activity but negative for effector caspase activity; the double-positive fraction represents
dead cells (yellow).
4.3 Pore formation converts a gradual buildup of pro-apoptotic signal into a switch-like
commitment to death
Our group has previously shown that cells enter a protracted and variable delay period in
which upstream initiator caspases are active but downstream effector caspases are inactive
(Albeck, Burke et al. 2008b). A subsequent sudden transition marks activation of the
downstream effector caspases that rapidly dismantle the cell. To understand how the extrinsic
apoptosis switch functions in quantitative terms, a mathematical model was constructed based on
a mass-action representation of known reaction pathways. The trained model accurately
reproduces the behavior of normal and perturbed cells exposed to TRAIL, making it possible to
study switching mechanisms in detail. Model analysis shows that the snap-action control of
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effector caspase activation is achieved by reactions involved in permeabilization of the
mitochondrial membrane and consequent relocalization of proteins such as Smac.
4.3.1 MOMP is complete by the time dying cells have assembled relatively few pores
Two testable predictions arise from the simulations described in (Albeck, Burke et al.
2008b) (i) Smac release should begin nearly simultaneously with the formation of the first Bax-
containing pores, and (ii) pore formation should continue long after Smac release is complete.
To test these predictions, cells expressing GFP-Bax and IMS-RP were treated with TRAIL (50
ng/ml) and imaged at 60x resolution at 30 sec intervals for 1 hour before and after MOMP. The
rate of release of IMS-RP was estimated using an edge-detection algorithm sensitive to the
transition from clustered IMS-RP signals diagnostic of mitochondrial localization to diffuse
signals diagnostic of cytosolic localization. In agreement with previous studies (Wolter, Hsu et
al. 1997) and the assumptions in EARMvl.0, GFP-Bax had a diffuse cytosolic localization prior
to MOMP but, in dying cells, formed bright puncta that co-localized with mitochondria (as
marked by IMS-RP; Fig. 4.5a). Moreover, GFP-Bax puncta appear to be identical to puncta
detected by immunofluorescence microscopy (not shown), suggesting that GFP-Bax is
representative of endogenous Bax. Appearance of the first GFP-Bax puncta coincided with IMS-
RP translocation, which appeared to be complete with within 1-2 frames (- 1 min), after which
puncta continued to form for 20-30 min more, typically rising to >100 per cell by the time cells
began to fragment (at which point further observation was unreliable; Fig. 4.5b). Live-cell
studies by others using similar methods have also demonstrated a close temporal link between
initial formation of Bax puncta and MOMP (D.R. Green, personal communication). We often
observed that the timing of MOMP varied with location in a cell, such that IMS-RP release from
some mitochondria preceded release from other mitochondria by -1 frame (30 seconds; Fig.
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4.5c). In these cases, the first observable Bax punctum was associated with the earliest-releasing
subset of mitochondria.
A similar relationship was observed between aggregation of Bak-GFP (a second pore-
forming protein involved in MOMP) and IMS-RP translocation, with the exception that Bak-
GFP was found on the mitochondrial membrane prior to MOMP (Nechushtan, Smith et al.
2001). The first appearance of Bak-GFP puncta was coincident with IMS-RP translocation and
puncta once again continued to form for >20 min thereafter (Fig. 4.5d). In contrast, GFP-Bcl-2
and GFP-Bcl-XL exhibited diffuse mitochondrial localization throughout, with no apparent
changes during MOMP (data not shown). Bid-GFP remained in the cytosol before, during, and
after MOMP, suggesting that tBid dissociates from Bax and Bak prior to pore formation (some
Bid-GFP aggregates were visible once membrane blebbing and cell shrinkage had begun but
only long after MOMP was complete; data not shown).
The precise relationship between functional translocation pores and visible GFP-Bax/Bak
puncta is not known, and puncta visible by live-cell imaging almost certainly contain more than
the 4-8 Bax or Bak subunits thought to comprise functional pores (Nechushtan, Smith et al.
2001). However, the close temporal and spatial association between puncta and IMS-RP release
(particularly at different locations in a single cell) implies that puncta may be clusters of pores.
Regardless, experiments clearly confirm our two model based predictions (i) that cytosolic
translocation of mitochondrial intermembrane proteins is complete by the time a small number of
pores have formed and (ii) that pores continue to form long afterward. Modeling also provides a
possible explanation for this latter phenomenon: overshoot in pore forming reactions guarantees
that the release of intermembrane proteins is sudden and complete regardless of variations in the
rate of initial pore formation.
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Figure 4.5. Formation of GFP-Bax and GFP-Bak puncta in synchrony with MOMP in HeLa cells.
a, Live-cell imaging of IMS-RP (red) and GFP-Bax (green) in the same cell. Frames correspond to 30-second inter-
vals, with the first frame of MOMP denoted by a pink box. Partial mitochondrial localization of IMS-RP following
MOMP is an artifact of the over-expressed reporter; endogenous cytochrome c is fully cytosolic at this point, as
determined by imunofluorescence (not shown). b, Quantitation of Bax pores (top) and rate of IMS-RP release
(bottom) for two cells (orange curves correspond to the cell shown in (a)); puncta and rate of release were quantified
as described in Materials and Methods. c, Live-cell images for the cell in (a) shown at higher zoom and with pseudo-
coloring to highlight the temporal and spatial relationship between Bax puncta and IMS-RP release. Frames corre-
spond to 30-second intervals; the magnified region (yellow box) encompasses the area of the cell in which both
GFP-Bax puncta and IMS-RP release are first visible. d, The localization of Bak-GFP and IMS-RP are shown as raw
images and as processed images after the application of an edge-detection filter. The first frame in which IMS-RP is
detected is highlighted by a yellow border; in the same frame, the first GFP-Bak puncta appear (arrow heads). As
expected for functionally redundant proteins involved in pore formation, GFP-Bax and GFP-Bak both form oligomeric
clusters simultaneous with Smac release and continue to form clusters long after Smac release has been completed.
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4.4 Future directions
The observations in Section 4.1 represent progress toward understanding the biochemical
differences in cells that undergo MOMP and cells that do not. However, knowledge of the rate
of cleavage of initiator caspase substrates and the amount cleaved at the time of MOMP only
partially distinguish surviving and dying cells. This is likely because induced survival pathways
also play a role in determining the fate of the cell. A cell's fate can be thought of as a race
between the post-translational caspase cascade and survival pathways transcriptionally induced
by NF-KB. Such a race could be monitored using IC-RP and NF-KB tagged with mCherry to
monitor NF-,B translocation. Alternatively, the effects of NF-B translocation could be
monitored by imaging fluorescent protein production driven by a KB promoter (Nelson,
Ihekwaba et al. 2004).
A more basic method of understanding the upstream dynamics of cells treated with
TRAIL involves immunoblotting of cleaved initiator caspase substrates after treatment.
Modeling suggests that in cells that survive TRAIL stimulation, most of the Bid has been
processed to tBid before MOMP is able to occur. Conversion of all Bid to tBid combined with
rapid degradation of tBid could delay MOMP indefinitely, as a certain amount of tBid is needed
to overwhelm the anti-apoptotic buffer at the mitochondria. Thus, cells on the low end of the
endogenous Bid protein distribution (mean = 60,000 proteins/cell; 5 th - 9 5 th percentile = 36,000 -
90,000) could potentially exhaust their supply of uncleaved Bid before the cell nears the MOMP
threshold. The conversion of Bid to tBid can be monitored in aggregate by immunoblotting to
determine the average time at which all of the Bid has been cleaved. Cells remaining alive after
that point will be much less likely to die, as any further signal from the receptor will be unable to
be transmitted to the mitochondria, at least via Bid. Indeed, a strong knockdown of Bid can
-111-
prevent MOMP (Albeck, Burke et al. 2008a). Perhaps cells that undergo MOMP at late times
upregulate other Bid homologs, such as Bim.
Overexpression of anti-apoptotic Bcl-2 family members is associated with an array of
cancers. Various anti-cancer therapies, such as the BH3 mimetic ABT-737, therefore target the
mitochondrial apoptosis pathway in an effort to lower the barrier for MOMP. Cell-permeable
BH3 peptides can also be used to modulate the MOMP threshold. The combination of IC-RP
and IMS-RP provides a means to measure the height of the MOMP threshold in single dying
cells to address the critical issue of how such drugs alter the MOMP threshold. Additionally, in
'primed' cancer cells that are sensitive to ABT-737 as a single agent, monitoring MOMP
simultaneously with pore formation using Bax-GFP and Bak-GFP will provide insight into its
mechanism of action in living cells.
The MOMP threshold can also be modulated in living cells by overexpressing
fluorescently tagged pro- and anti-apoptotic proteins to different degrees. In Chapter 3, I
demonstrated the existence of a very sharp threshold in Bcl-2 and Bcl-xL protein levels above
which cells completely resist MOMP. A next step will be to concomitantly express, at varying
levels, different pro-apoptotic proteins to determine how many of each protein is required to
neutralize Bcl-2 and Bcl-xL, thereby allowing MOMP. Of particular interest will be the
comparison between "activator" proteins such as Bid, "effector" proteins such as Bax and Bak,
and "sensitizer" proteins such as Noxa and Bad, whose purpose seems to involve the fine-tuning
of the MOMP threshold (Letai, Bassik et al. 2002).
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Chapter 5
5 Conclusions
5.1 Summary of major contributions
The goal of this thesis was to understand the origins of variability in both the timing and
the probability of death in TRAIL-induced apoptosis. To this end, I employed both experimental
and computational methods to show that natural variability in protein levels can be a major
contributor to variability in sensitivity to TRAIL within a clonal population of cells.
In Chapter 2, I experimentally addressed the sources of cell-to-cell variability in the
timing of TRAIL-induced apoptosis. The sister cell studies provide strong causal evidence for
variability in initial conditions and argue against other possible causes of variability (cell cycle,
genetic mutation, stochasticity in the signaling reactions activated by TRAIL). I then
demonstrated the short-term heritability of this phenotype and measured its rate of decay in the
presence and absence of protein translation. Last, I performed a detailed analysis of the relative
contributions of three pieces of the TRAIL pathway (upstream, downstream, and at MOMP) to
variability in death time. This included analysis of the rate of initiator caspase product
accumulation in single cells, which I found to be highly predictive of a cell's death time.
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In Chapter 3, I used a differential equation model for TRAIL-induced apoptosis (Albeck,
Burke et al. 2008b) to examine the impact of variability in protein levels on variability in the
timing of death. These simulations showed that the endogenous variability in apoptotic
regulators was sufficient to produce the observed variability in death time. A sensitivity analysis
followed by experimentation revealed that moderate changes in the levels of protein regulators of
MOMP, such as Bcl-2, can have a large impact on the fate of a cell. Finally, despite the fact that
variability in protein levels is the cause of variability in death time in our simulations, knowing
the concentration of any single protein in the pathway has minimal value in predicting a cell's
death time because variation in all other proteins masks the underlying trends.
In Chapter 4, I examined the differences between cells that resist MOMP to survive
TRAIL treatment and cells that die, within a genetically identical population. Cells that survive
an initial TRAIL treatment are immune to a subsequent challenge with TRAIL, but this
resistance decays over time. I found that the height of the MOMP threshold could partially
differentiate between cells that were susceptible and cells that were resistant to death. Lastly, I
measured a close temporal and spatial association between the initial appearance Bax and Bak
puncta (presumably clusters of pores) and the onset of MOMP, narrowing in on the reactions that
convert a gradual buildup of pro-apoptotic signal to a switch-like commitment to death.
5.2 Relevance of this work
5.2.1 Evolutionary advantages and disadvantages of variability
One can imagine non-genetic variability as an advantageous characteristic that cells can
exploit or as a disadvantage for cells trying to achieve robust behavior. In unicellular organisms,
noise could be useful in allowing isogenic populations of cells to attain heterogeneity in
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phenotype, which they cannot otherwise do. In stressful or fluctuating environments, such as
food shortage, two options exist - cells can either sense a new food source in the environment
and then activate the required metabolic networks, or they can pre-commit a fraction of the
population to have this metabolic network active constitutively (Raj and van Oudenaarden 2008).
The tradeoff in the first strategy is slow response time, whereas the second strategy sacrifices a
subset of cells to suboptimal growth (Raj and van Oudenaarden 2008). A striking example of
this bet-hedging is bacterial persistence. Persistent cells grow at a slower rate than other cells,
but tend to be more resistant to antibiotic exposure. Using live-cell imaging, one group found
that a small fraction of E. coli always survive an antibiotic treatment; these persistent cells were
not genetically resistant mutants, as cells re-grown from this population were sensitive to
antibiotics (Balaban, Merrin et al. 2004). Instead, persistence was linked to pre-existing (as
opposed to induced) heterogeneity in the population and could be clearly detected before
treatment due to the reduced growth rate of persistent cells (Balaban, Merrin et al. 2004). The
fact that slow-growing persistent cells and rapidly-growing non-persistent cells can stochastically
interconvert suggests a possible role for noise in gene expression. A better understanding of this
switching process has medical relevance for the antibiotic treatment of Mycobacterium
tuberculosis, where persistence is a treatment obstacle (Stewart, Robertson et al. 2003).
In the case of TRAIL-mediated apoptosis addressed in this thesis, cells have not been
observed to exist in such noticeably discrete susceptible and resistance states prior to treatment.
Nevertheless, cells treated with TRAIL alone subdivide neatly into cells that die and cells that
survive with no visible trauma - survivors continue to divide at the same rate as untreated cells
(S.L.S. unpublished observations). This is a testament to the "stiff trigger", "all-or-nothing"
nature of the apoptotic switch - cells that cross the threshold for MOMP are fully committed to
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die, while cells that do not must be able reset to their healthy pre-treatment state. Yet the
question remains why the system has evolved such that only a fraction of cells respond to TRAIL
treatment. Is there any possible benefit to such a variable response? For normal cells during
development or adult homeostasis, variability in sensitivity to apoptosis provides a way to bring
about a graded response at a cell population or tissue level, despite a binary output at the single
cell level. In the case of cancer, since a tumor cell's apoptotic program can be triggered by
oncogene overexpression, increased variability in sensitivity to apoptosis may allow a few cells
to survive this anti-cancer defense mechanism and expand to form a tumor. In a population with
no phenotypic variability, a sudden environmental fluctuation could kill the entire population,
whereas in a phenotypically diverse population, a few members might survive the insult (e.g. due
to transient, higher than average levels of some protective factor). Indeed, two studies that used
flow cytometry to monitor the levels of many GFP-tagged proteins in yeast revealed that proteins
that respond to stress have unusually large cell-to-cell variability (Bar-Even, Paulsson et al.
2006; Newman, Ghaemmaghami et al. 2006). If a population of isogenic cells contains members
that are significantly better suited to a new environment than the population average, and if these
advantageous traits are at least transiently heritable due to slow mixing rates, these traits can be
temporarily selected for in a process similar to Darwinian selection. Although the cells may lose
their fitness advantage over time due to the non-genetic nature of trait, this fitter subpopulation
can temporarily expand and increase the chances of acquiring permanent genetic mutations.
Perhaps it is in these cells that advantageous genetic changes first arise and become fixed.
In situations where variability is disadvantageous, organisms may have developed
mechanisms to suppress this variability. For example, these same two flow cytometry studies in
yeast found that genes involved in protein synthesis and degradation exhibited much less
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variability than the stress response genes, raising the possibility that genes that are essential for
cellular function require higher precision in their protein levels (Bar-Even, Paulsson et al. 2006;
Newman, Ghaemmaghami et al. 2006). Additionally, the presence of negative feedback loops
may reveal situations where an otherwise variable output (in the absence of negative feedback)
would be deleterious. In the case of receptor-mediated apoptosis, the presence of a dose-
dependent variable delay period preceding MOMP followed by a dose-independent and nearly
invariant post-MOMP period likely reflects the evolutionary advantages of such a system. The
advantage of a rapid and nearly invariant switch should be to prevent cells from initiating but not
completing apoptosis, thereby preventing the formation of "undead" pre-cancerous cells with
partially cleaved genomes and resulting chromosomal rearrangements (Albeck, Burke et al.
2008a).
5.2.2 Cancer stem cells
Variability in the tumorigenicity of cancer cells is a commonly observed phenomenon. In
many studies, individual cells or subpopulations of cells obtained from tumors are assayed for
tumorigenicity, revealing large variability in the malignancy of individual cancer cells (Brock,
Chang et al. 2009). These observations have traditionally been explained by genetic differences
among cells within a tumor. More recently, such observations have been considered evidence
for the existence of cancer stem cells. Cancer stem cells have been defined as "rare cells with
indefinite potential for self-renewal that drive tumorigenesis" (Reya, Morrison et al. 2001). The
existence of such rare cells has important implications for cancer therapy, as normal stem cells
tend to be more resistant to chemotherapy than mature cells from the same tissue (Reya,
Morrison et al. 2001). If the same were true of cancer stem cells, these cells might also have
-117-
increased resistance to chemotherapy, and new therapies would need to be developed to
specifically target these cells.
The evidence for cancer stem cells relies on findings that only a small subset of cancer
cells is capable of extensive proliferation (Reya, Morrison et al. 2001). The creation of
immunodeficient mice that can tolerate the growth of human cancer cells allowed researchers to
address experimentally whether all cancer cells have the ability to form tumors, or whether this
property is restricted to a unique subset (the cancer stem cells). A series of studies performed in
non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice showed that only a
small fraction of cells (0.0001-0.1%) have the ability to produce a tumor (Bonnet and Dick 1997;
Al-Hajj, Wicha et al. 2003; Singh, Hawkins et al. 2004; O'Brien, Pollett et al. 2007; Ricci-
Vitiani, Lombardi et al. 2007; Eaves 2008; Schatton, Murphy et al. 2008). These studies found
that the cells with tumorigenic potential have cell surface markers similar to those on normal
stem cells of the same tissue. These findings supported the notion that the cancer cells that could
actually populate a tumor represent a distinct subset having similarity to stem cells.
However, a recent report using even more highly immunocompromised mice
demonstrated the formation of tumors from single-cell transplants of unselected melanoma cells
(Quintana, Shackleton et al. 2008). The authors found that 27% or about one in four individual
melanoma cells formed tumors under these more permissive conditions, indicating that cells with
tumorigenic potential are more common than the cancer stem cell hypothesis originally proposed
(Quintana, Shackleton et al. 2008). The authors then assessed whether the tumorigenic
melanoma cells were phenotypically distinct from melanoma cells that failed to form tumors.
Many proteins shown to mark cancer stem cell populations in other studies were tested, but in
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every case, tumors arose from all fractions of cells despite heterogeneous expression of these
proteins.
One protein tested was CD133, a cell surface marker commonly expressed on stem cells
whose presence was previously shown to increase tumorigenicity 200-fold (O'Brien, Pollett et al.
2007). Interestingly, tumors derived from either CD133 + or CD133- cells were later found to
contain both CD133 + and CD133- cells, irrespective of the pool of cells from which they were
derived (Quintana, Shackleton et al. 2008). The time-scale of such "re-mixing" has been
examined for 20 proteins (Sigal, Milo et al. 2006); remixing has also been independently
observed for two stem cell markers, Nanog and Sca-1 (Chambers, Silva et al. 2007; Chang,
Hemberg et al. 2008). These results raise the possibility that cancer cells that are capable of
forming tumors are not necessarily genetically or epigenetically distinct, static entities. Rather,
noise in gene expression could transiently create subpopulations of cells that express a specific
set of initial conditions that favors tumor formation. Indeed, a report from 25 years ago found
that the majority of melanoma cells were non-metastatic, but the cells that did possess metastatic
potential were unstable and lost at very high rates (Hill, Chambers et al. 1984; Ling, Chambers et
al. 1984). The authors dubbed such rapid variations "dynamic heterogeneity", which could be
due to genomic instability or possibly non-genetic cell-to-cell variability.
5.2.3 Fractional killing of tumors
Understanding the sensitivity and resistance of tumors to drug treatment, both across
cancer types and within a single tumor, is critical for effective treatment. It is well known
clinically that one round of chemotherapy does not kill all the cells in a tumor, a poorly
understood phenomenon known as "fractional cell kill." The fractional kill hypothesis states that
a defined chemotherapy concentration applied for a defined time period will kill a constant
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fraction of the cells in a population, independent of the absolute number of cells (Berenbaum
1972; Skipper 1979; Chabner and Longo 2006). In solid tumors, access of the drug to the tumor
can limit the fraction of tumor cells killed, but the validity of the fractional kill hypothesis has
been established in animal models of leukemia as well as in human leukemia and lymphoma,
where drug access is less of an issue (Chabner and Longo 2006). Because only a fraction of the
cells die with each treatment, repeated doses must be administered to continue to reduce the size
of the tumor (Skeel 2003). Current chemotherapy regimens apply drug treatment in cycles, with
the frequency and duration of treatments limited by toxicity to the patient (Chabner and Longo
2006). The goal is to reduce the tumor population to zero with successive fractional kills
(Chabner and Longo 2006). For example, assuming a 99% kill per cycle of chemotherapy, a
tumor of 1011 cells would be reduced to less than one cell with six treatment cycles: 1011 * 0.016
< 1 (Chabner and Longo 2006). However, the tumor can also re-grow during the intervals
between treatments, limiting the net reduction of each fractional kill (Skeel 2003).
The fractional killing of tumors in response to treatment is assumed to be due to the cell
cycle specificity of chemotherapy drugs (Skeel 2003; Chabner and Longo 2006). Cytarabine, a
DNA-synthesis inhibitor also known as ara-C, is cited as the classic cell cycle phase-specific
agent (Skeel 2003). Chemotherapy dosing schedules have been optimized based on the fact that
cytarabine is only expected to be effective in the DNA synthesis (S) phase of the cell cycle
(Skeel 2003). Consistent with this, leukemia patients respond better to cytarabine treatments
given every 12 hours rather than every 24 hours. This finding that can be explained by the fact
that S-phase in these leukemia cells lasts 18-20 hours, allowing some cells to escape the
cytotoxic effect of the drug if it is given every 24 hours (Skeel 2003). However, alternative
explanations are possible, as described below. A trace through the literature on the S-phase
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specificity of cytarabine leads to literature that simply assumes S-phase specificity based on
cytarabine's reported site of biochemical action (Skipper, Schabel et al. 1970), which the later
papers reference.
Very little direct information is available on whether cells undergo apoptosis from a
certain point in the cell cycle (Cotter, Glynn et al. 1992). One study which did address this topic
used flow cytometry or elutriation of synchronized cells treated with actinomycin Dl,
camptothecin, or aphidicolin, each of which had been documented to exert its effects in a
particular phase of the cell cycle (Cotter, Glynn et al. 1992). Surprisingly, the authors found that
each of the agents was able to induce apoptosis in all phases of the cell cycle, suggesting that the
mechanism through which the drugs induce apoptosis may be independent of the drugs'
biochemical targets (Cotter, Glynn et al. 1992). The lack of cell cycle effect for camptothecin
has been confirmed recently in a live-cell microscopy study (Cohen, Geva-Zatorsky et al. 2008).
To my knowledge, a concerted effort has not been undertaken to prove the phase specificity of
classic chemotherapy drugs, upon which explanations of fractional kill currently rely. These
assumptions would be worth testing using modern cell biology methods, for example with time-
lapse imaging of the recently published cell cycle phase reporters (Sakaue-Sawano, Kurokawa et
al. 2008).
Indeed, this thesis raises the possibility that cell-to-cell variability in protein
concentrations may contribute to fractional killing in the case of TRAIL treatment. I have
observed fractional killing at a single cell level in every cell line examined, even in genetically
identical populations grown in homogenous environments, and have ruled out the conventional
explanation (cell cycle effects) in two of these lines. Variability in the timing and probability of
death is not simply a feature of TRAIL treatment, as variability in response has been observed in
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cells treated with both ionizing radiation and many other cancer drugs in clinical use including
camptothecin and taxol (Lahav, Rosenfeld et al. 2004; Geva-Zatorsky, Rosenfeld et al. 2006;
Cohen, Geva-Zatorsky et al. 2008; Gascoigne and Taylor 2008). More likely, variability in cell
fate will eventually be regarded as a general feature of apoptotic response. A better
understanding of the determinants of fractional kill in the controlled environment of a cell culture
system should contribute to the understanding of fractional killing in tumors, and could
ultimately have ramifications for the dosing and timing of chemotherapy treatment in patients.
5.3 Future Directions
A number of possible lines of future study stem from this thesis. A priori prediction of
which cells will live and which cells will die in response to TRAIL as well as other drugs
remains elusive. In the continued quest to understand this non-genetic variability in cell fate,
two lines of experimentation using time-lapse microscopy could be informative. In the context
of TRAIL-induced apoptosis, endogenously tagging (for example, using adeno-associated virus
technology) (Rago, Vogelstein et al. 2007) the most sensitive species in the pathway with
fluorescent proteins would be valuable. This would facilitate measurement of the timescales of
fluctuations in key proteins such as Bid, Bax, and Bcl-2 and could potentially enable prediction
of cell fate. If successful, variability in cell fate could be definitively demonstrated to be a
function of transient fluctuations in protein levels. A second set of fruitful live-cell microscopy
experiments would involve using the newly published fluorescent cell cycle reporters (Sakaue-
Sawano, Kurokawa et al. 2008) to screen a panel of cancer drugs for potential cell cycle phase
dependence. As discussed above, cell cycle effects on variability in drug response are likely to
be less prominent than currently assumed.
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Currently, the time between chemotherapy treatments is determined largely by toxicity to
the patient; the next dose is given as soon as the patient is able to tolerate an additional dose of
the drug. However, given my observations of fractional killing by TRAIL and the timescales of
transient resistance to re-treatment, perhaps the commonly used dosing regimen is sub-optimal.
For example, this thesis suggests that tumor cells that survive an initial treatment with TRAIL
one day may be completely resistant to treatment one or two days later. In this case, re-treating
the tumor too soon could waste expensive drugs and cause unnecessary toxicity to the patient;
conversely, allowing too much time to elapse between treatments would permit the surviving
cells to replenish the tumor, negating any progress in tumor eradication. The data gathered in
this thesis could be used to build and calibrate a mathematical model that would take into
consideration a particular cancer cell type's rate of decay of transient resistance, the cancer cell
type's doubling rate, and a drug's fractional kill to forecast the optimal chemotherapy dosing
scheme. Perhaps a lower concentration and more frequent dosing based on model predictions
would be more effective than a maximally tolerated dose given at the shortest possible interval.
Model predictions could be tested in cancer cell lines and later in mice carrying xenografts of
human tumors.
The identification of biomarkers to select patients whose cancers will be sensitive to
TRAIL would be clinically valuable (Ashkenazi and Herbst 2008). Many studies have examined
possible causes of sensitivity or resistance to TRAIL across cancer cell lines in experiments that
measure one or a few nodes in the pathway. However, even among genetically identical cells
grown in a homogenous environment, the response to TRAIL is complex and heterogeneous. As
this thesis shows, single gene measurements are not likely to predict sensitivity or resistance to
death-inducing agents. The life-or-death decision is made by a complex network of interacting
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proteins whose levels and states govern the fate of the cell. Therefore, simultaneous
measurement of many network nodes to assess the state of the cell will be necessary for
prediction of a particular cell type's susceptibility to TRAIL. One approach that is currently
underway in our lab involves the use of Luminex's xMAP technology to multiplex
measurements of up to 17 protein levels or states of apoptotic regulators.
Our model of TRAIL-induced apoptosis contains several estimated parameter values, such
as initial conditions and reaction rates. Thus, there may be multiple parameter sets that could
produce the basic dynamics of the signaling pathway. An important future direction for
parameter estimation and model calibration involves using single cell experimental data to
constrain parameter values. Our group now has a large collection of dynamic single cell data of
perturbed and wild-type cells that can be used for automated calibration of the model. The
measurements of cell-to-cell variability described in this thesis are optimal for a Bayesian
statistical approach using Markov Chain Monte Carlo techniques. This approach combines prior
information regarding model parameters with information in the data to produce a distribution of
possible parameter values (Wilkinson 2009). These resulting distributions should anticipate
future measurements of heterogeneity in protein levels, a key contributor to variability in
apoptosis.
5.4 Closing thoughts
I hope that this thesis brings awareness of the potential of non-genetic variability to
influence many diverse processes, including apoptosis. The findings described here have
relevance to understanding the dynamics of natural selection, the malignant potential of
individual cancer cells, as well as fractional killing in cancer treatment. In general, my work
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suggests that non-genetic factors can have an unanticipated role in explaining sensitivity and
resistance to chemotherapy
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